<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00812929</url>
  </required_header>
  <id_info>
    <org_study_id>112025</org_study_id>
    <nct_id>NCT00812929</nct_id>
  </id_info>
  <brief_title>A Clinical Trial to Test a Study Drug in Volunteers Who Develop Asthma Following Exercise</brief_title>
  <official_title>A Multi-centre, Randomized, Double-blind, Five-way Crossover Study Evaluating the Dose Response and Duration of Action of GSK2190915 Compared to Placebo in Subjects With Mild Asthma Who Experience Exercise Induced Bronchoconstriction.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is intended to determine the dose response and duration of action of GSK2190915 in
      mild asthmatic adult subjects who experience exercise-induced bronchoconstriction.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is intended to determine the dose response and duration of action of GSK2190915 in
      mild asthmatic adult subjects who experience exercise-induced bronchoconstriction. Subjects
      will be invited to complete a screening visit, during which time exercise induced
      bronchoconstriction must be demonstrated, defined as a decrease between 20-40% in FEV1
      compared to baseline immediately following exercise challenge. Eligible subjects will
      complete a randomized, double-blind, five-way crossover study. Subjects will be randomized to
      a single dose of either 10 mg, 50 mg, 100 mg, 200 mg GSK2190915, or placebo during each
      treatment period. Each treatment period will last 2 days and will include various assessments
      following exercise challenge at 2, 9.5, and 24 hours post dose. A minimum 7 day washout
      between treatment periods will be required. Regardless if a subject completes or prematurely
      withdraws from the study, a follow up visit will be completed 7-21 days following last dose.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 1, 2008</start_date>
  <completion_date type="Actual">July 15, 2009</completion_date>
  <primary_completion_date type="Actual">June 1, 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximal Percentage Change From Pre-exercise Baseline Forced Expiratory Volume in 1 Second (FEV1) to the Minimum FEV1 Collected Within 60 Minutes Following the Exercise Challenge at 24 Hours Post Dose</measure>
    <time_frame>Baseline (pre dose) and 60 minutes following the exercise challenge at 24 hours post dose of each treatment period.</time_frame>
    <description>FEV1 was recorded in triplicate, with participant encouraged to inhale fully despite any presence of chest tightness. For FEV1, a pre-challenge Baseline was defined for each challenge time point as maximum of triplicate measurements performed prior to challenge. The maximal percentage change within 60 minutes following exercise challenge was derived by taking minimum (i.e., most negative) percentage change in FEV1 over 5, 10, 15, 30, 45 and 60 minutes post challenge. Percent change FEV1 = 100*(FEV1 - Pre-challenge FEV1)/ Pre-challenge FEV1. If the exercise challenge was not completed successfully (i.e. heart rate maintained at &gt;=80% of the predicted value for 6 minutes), FEV1 maximal percent change (0-60)was set to be missing. Analysis was performed using a mixed effects model, including period, treatment and covariates for predose FEV1. Estimates and 95% confidence intervals for treatment difference between each active dose and placebo for each challenge time point were calculated.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximal Percentage Change From Pre-exercise Baseline FEV1 to the Minimum FEV1 Collected Within 60 Minutes Following the Exercise Challenge at 2 and 9.5 Hours Post Dose</measure>
    <time_frame>Baseline (pre dose) and 60 minutes following the exercise challenge at 2 and 9.5 hours post dose of each treatment period.</time_frame>
    <description>FEV1 was recorded in triplicate, with participant encouraged to inhale fully despite any presence of chest tightness. For FEV1, a pre-challenge Baseline was defined for each challenge time point as maximum of triplicate measurements performed prior to challenge. The maximal percentage change within 60 minutes following exercise challenge was derived by taking minimum percentage change in FEV1 over 5, 10, 15, 30, 45 and 60 minutes post challenge. Percent change FEV1 = 100*(FEV1 - Pre-challenge FEV1)/ Pre-challenge FEV1. If the exercise challenge was not completed successfully (i.e. heart rate maintained at &gt;=80% of the predicted value for 6 minutes), the FEV1 maximal percent change (0-60)was set to be missing. Analysis was performed using a mixed effects model, including period, treatment and covariates for predose FEV1. Estimates and 95% confidence intervals for treatment difference between each active dose and placebo for each challenge time point were calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weighted Mean (WM) for FEV1 Percentage Change From Baseline Recorded During 0 to 60 Minutes Following Exercise Challenge (FEV1 WM0-60)</measure>
    <time_frame>Baseline (pre dose) and 0 to 60 minutes following exercise challenge at 2, 9.5 and 24 hours post dose of each treatment period.</time_frame>
    <description>FEV1 was recorded in triplicate, with participant encouraged to inhale fully despite any presence of chest tightness. For FEV1, a pre-challenge Baseline was defined for each challenge time point as maximum of triplicate measurements performed prior to challenge.Weighted mean FEV1 percentage change recorded during 0-60 minutes post challenge was determined for each challenge, by dividing area under curve (AUC) for percent change from Baseline FEV1 measurements at 5, 10, 15, 30, 45 and 60 minutes post challenge by time interval. Actual times were used to determine time interval where available; otherwise planned relative time was used. If one or more FEV1 values were missing, AUC was calculated over time interval of available values. If intermittent values were missing over a participant's profile,it was assumed to be linear between 2 available values for calculation of AUC. Analysis was performed using a mixed effects model, including period, treatment and covariates for predose FEV1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to FEV1 Recovery to Within 5 Percent of Baseline Following Exercise Challenge</measure>
    <time_frame>0 to 60 minutes following exercise challenge at 2, 9.5 and 24 hours post dose of each treatment period</time_frame>
    <description>The time from maximal percentage change in FEV1 to recovery to within 5% of pre challenge Baseline (in minutes) was derived using actual sampling times. Time to FEV1 recovery= [SAS date/time of recovery(a) FEV1 - SAS date/time of FEV1 Maximum % Change0-60] / 60, where &quot;a&quot; is earliest recorded FEV1 either above pre-challenge Baseline or within 5% below pre challenge Baseline. Any unscheduled FEV1 measurements taken after last scheduled post challenge measurement was considered when deriving this endpoint. A corresponding censoring variable was derived for analysis to indicate whether recovery to within 5% of pre-challenge Baseline was achieved. The censoring variable was set to 1 if recovery to within 5% of Baseline was achieved. If recovery was not evident from data collected, time to recovery was calculated using the date/time of the last available post challenge FEV1 assessment and censoring variable was set to zero. Analysis was performed using a Cox proportional hazards model.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Using a Short Acting Beta-2 Agonist (Rescue Medication) During 0 to 90 Minutes Following Exercise Challenge</measure>
    <time_frame>0 to 90 minutes following exercise challenge of each treatment period</time_frame>
    <description>Rescue medication was provided to participants at any time and it was strongly recommended for participants with a FEV1 decrease of at least 40% following exercise challenge compared to Baseline. Rescue medication was administered 0 to 90 minutes post exercise challenge. Statistical analysis was supposed to be performed using logistic regression, however, the data was too sparse to permit any formal statistical analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Vital Signs: Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)</measure>
    <time_frame>Pre dose, 2 hours, 9.5 hours and 24 hours prior to exercise challenge of treatment period</time_frame>
    <description>All participants rested for at least 10 minutes in the supine position prior to vital signs recordings. Vital signs Baseline values for SBP and DBP for each treatment period were calculated using the mean value of triplicate pre dose readings. Triplicate readings were taken at least five minutes apart. Assessment was performed at pre dose, 2 hours, 9.5 hours and 24 hours prior to exercise challenge.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Vital Signs: Heart Rate (HR)</measure>
    <time_frame>Pre dose, 2 hours, 9.5 hours and 24 hours prior to exercise challenge of each treatment period</time_frame>
    <description>All participants rested for at least 10 minutes in the supine position prior to vital signs recordings. Vital signs Baseline values for HR for each treatment period were calculated using the mean value of triplicate pre dose readings. Triplicate readings were taken at least five minutes apart. Assessment was performed at pre dose, 2 hours, 9.5 hours and 24 hours prior to exercise challenge.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Abnormal Electrocardiogram (ECG) Findings</measure>
    <time_frame>Pre dose, 2 hours, 9.5 hours and 24 hours prior to exercise challenge and 60 minutes following exercise challenge at 2 hours of each treatment period</time_frame>
    <description>All participants rested for at least 10 minutes in the supine position prior to ECG recordings. ECG Baseline values for each treatment period was calculated using the mean value of triplicate pre dose readings. Triplicate readings were taken at least five minutes apart. Assessment was performed at pre dose, 2 hours, 9.5 hours, 24 hours prior to exercise challenge and 60 minutes following exercise challenge at 2 hours. Participants with not clinically significant (NCS) abnormal values were reported. Potential clinical importance range for the ECG parameters are as follows: absolute QTc interval &gt;450 millisecond (msec), increase from Baseline QTc &gt;60 msec, PR interval &lt;110 and &gt;220 msec and QRS interval &lt;75 and &gt;110 msec. No participants reported clinically significant abnormal values.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Clinical Chemistry Parameters: Albumin, Total Protein</measure>
    <time_frame>Pre dose and 25 hours and 30 minutes post dose of each treatment period</time_frame>
    <description>Blood samples were collected for the assessment of clinical chemistry parameters for albumin and total protein at pre dose and 25 hours and 30 minutes. Participants had to fast for at least 8 hours prior to visit. During treatment periods, fasting continued until a light meal was allowed 1 hour post dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Clinical Chemistry Parameters: Alkaline Phosphatase (ALP), Alanine Amino Transferase (ALT), Aspartate Amino Transferase (AST), Gamma Glutamyl Transferase (GGT)</measure>
    <time_frame>Pre dose and 25 hours and 30 minutes post dose of each treatment period</time_frame>
    <description>Blood samples were collected for the assessment of clinical chemistry parameters for ALP, ALT, AST and GGT at pre dose and 25 hours and 30 minutes. Participants had to fast for at least 8 hours prior to visit. During treatment periods, fasting continued until a light meal was allowed 1 hour post dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Clinical Chemistry Parameters: Direct Bilirubin, Total Bilirubin, Creatinine</measure>
    <time_frame>Pre dose and 25 hours and 30 minutes post dose of each treatment period</time_frame>
    <description>Blood samples were collected for the assessment of clinical chemistry parameters for direct bilirubin, total bilirubin and creatinine at pre dose and 25 hours and 30 minutes. Participants had to fast for at least 8 hours prior to visit. During treatment periods, fasting continued until a light meal was allowed 1 hour post dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Clinical Chemistry Parameters: Calcium, Chloride, Glucose, Potassium, Sodium, Urea/Blood Urea Nitrogen (BUN)</measure>
    <time_frame>Pre dose and 25 hours and 30 minutes post dose of each treatment period</time_frame>
    <description>Blood samples were collected for the assessment of clinical chemistry parameters for calcium, chloride, glucose, potassium, sodium and urea/BUN at pre dose and 25 hours and 30 minutes post dose. Participants had to fast for at least 8 hours prior to visit. Participants fasted for glucose blood sample. During treatment periods, fasting continued until a light meal was allowed 1 hour post dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Total Neutrophils (TN) (ANC - Absolute Neutrophil Count), Platelet Count, White Blood Cell Count (WBC)</measure>
    <time_frame>Pre dose and 25 hours and 30 minutes post dose of each treatment period</time_frame>
    <description>Blood samples were collected for the assessment of hematology parameters for basophils, eosinophils, lymphocytes, monocytes, TN, platelet count, WBC at pre dose and 25 hours and 30 minutes post dose. Participants had to fast for at least 8 hours prior to visit. During treatment periods, fasting continued until a light meal was allowed 1 hour post dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Hematology Parameters: Hemoglobin, Mean Corpuscle Hemoglobin Concentration (MCHC)</measure>
    <time_frame>Pre dose and 25 hours and 30 minutes post dose of each treatment period</time_frame>
    <description>Blood samples were collected for the assessment of hematology parameters for hemoglobin and MCHC at pre dose and 25 hours and 30 minutes post dose. Participants had to fast for at least 8 hours prior to visit. During treatment periods, fasting continued until a light meal was allowed 1 hour post dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Hematology Parameters: Hematocrit</measure>
    <time_frame>Pre dose and 25 hours and 30 minutes post dose of each treatment period</time_frame>
    <description>Blood samples were collected for the assessment of hematology parameters for hematocrit at pre dose and 25 hours and 30 minutes post dose. Participants had to fast for at least 8 hours prior to visit. During treatment periods, fasting continued until a light meal was allowed 1 hour post dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Hematology Parameters: Mean Corpuscle Hemoglobin (MCH)</measure>
    <time_frame>Pre dose and 25 hours and 30 minutes post dose of each treatment period</time_frame>
    <description>Blood samples were collected for the assessment of hematology parameter for MCH at pre dose and 25 hours and 30 minutes post dose. Participants had to fast for at least 8 hours prior to visit. During treatment periods, fasting continued until a light meal was allowed 1 hour post dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Hematology Parameters: Mean Corpuscle Volume (MCV)</measure>
    <time_frame>Pre dose and 25 hours and 30 minutes post dose of each treatment period</time_frame>
    <description>Blood samples were collected for the assessment of hematology parameter for MCV at pre dose and 25 hours and 30 minutes post dose. Participants had to fast for at least 8 hours prior to visit. During treatment periods, fasting continued until a light meal was allowed 1 hour post dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Hematology Parameters: Red Blood Cell Count (RBC)</measure>
    <time_frame>Pre dose and 25 hours and 30 minutes post dose of each treatment period</time_frame>
    <description>Blood samples were collected for the assessment of hematology parameter for RBC at pre dose and 25 hours and 30 minutes post dose. Participants had to fast for at least 8 hours prior to visit. During treatment periods, fasting continued until a light meal was allowed 1 hour post dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>Up to follow up (7 to 21 days) following last dose</time_frame>
    <description>An AE is any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect and medically significant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change From Baseline in Blood Leukotriene B4 (LTB4)</measure>
    <time_frame>Baseline (pre dose) up to 24 Hours post dose of each treatment period</time_frame>
    <description>Analysis LTB4 levels in the blood samples indicated the extent of LTB4 inhibition following administration of GSK2190915 compared to Baseline. Baseline was the pre dose value. Change from Baseline was calculated by subtracting the Baseline values from the individual post-randomization values.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change From Baseline in Urine Leukotriene E4 (LTE4)</measure>
    <time_frame>Baseline (pre dose) up to 24 Hours post dose of each treatment period</time_frame>
    <description>Analysis of LTE4 levels in the urine samples indicated the extent of LTE4 inhibition following administration of GSK2190915 compared to Baseline. Baseline was the pre dose value. Change from Baseline was calculated by subtracting the Baseline values from the individual post-randomization values.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Derived Pharmacokinetic (PK) Parameters for GSK2190915</measure>
    <time_frame>Pre dose, 2 hours, 3.5 hours, 9.5 hours, 11 hours and 24 hours following exercise challenge of each treatment period</time_frame>
    <description>PK samples were supposed to be collected at 10 minutes prior to the exercise challenge at 2 hours, 9.5 hours and 24 hours.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">47</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>GSK2190915 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>GSK2190915 50 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>GSK2190915 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>GSK2190915 200 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>The current study will include a placebo arm to allow for a valid evaluation of adverse events attributable to GSK2190915 versus those independent of GSK2190915.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK2190915</intervention_name>
    <description>This study will assess FEV1 at various intervals following exercise challenge in subjects who have been administered a single dose of 10 mg, 50 mg, 100 mg, or 200 mg GSK2190915, compared to a placebo control.</description>
    <arm_group_label>GSK2190915 10 mg</arm_group_label>
    <arm_group_label>GSK2190915 50 mg</arm_group_label>
    <arm_group_label>GSK2190915 100 mg</arm_group_label>
    <arm_group_label>GSK2190915 200 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females aged 18 to 55 years inclusive.

          -  Female subjects must be of non childbearing potential including pre-menopausal females
             with documented hysterectomy or double oophorectomy or tubal ligation or
             postmenopausal defined as 12 months of spontaneous amenorrhea or 6 months of
             spontaneous amenorrhea with serum FSH levels &gt; 40 mIU/mL and estradiol &lt; 40 pg/ml
             (&lt;140 pmol/L) or 6 weeks postsurgical bilateral oophorectomy with or without
             hysterectomy. Hormone replacement therapy (HRT) is permitted for post-menopausal
             females.

          -  Male subjects must agree to use one of the protocol outlined contraception methods.
             This criterion must be followed from the time of the first dose of study medication
             until 3 months after administration of last dose.

          -  Body weight greater than or equal to 50 kg and Body mass index within range of
             18.5-35.0 kg/m2 inclusive.

          -  Pre-bronchodilator FEV1 &gt;70% of predicted at screening.

          -  Exercise induced bronchoconstriction, as defined as a 20-40% decrease in FEV1 compared
             to baseline immediately following exercise challenge at screening.

          -  Current non-smokers who have not used any tobacco products in the 6-month period
             preceding the screening visit with a pack history of less than or equal to 10 pack
             years [number of pack years = (number of cigarettes per day/20) x number of years
             smoked]

          -  Has provided signed and dated written informed consent

          -  Is able to understand and comply with the protocol requirements, instructions and
             protocol-stated restrictions.

        Exclusion Criteria:

          -  Chronic use of inhaled corticosteroids (ICS) for the treatment of persistent asthma.

          -  Past or present disease, which as judged by the investigator or medical monitor, may
             affect the outcome of this study or the subject's safety. These diseases include, but
             are not limited to, cardiovascular disease, malignancy, hepatic disease,
             gastrointestinal disease, renal disease, haematological disease, neurological disease,
             endocrine disease or pulmonary disease (with the exception of asthma, but including
             chronic bronchitis, emphysema, bronchiectasis or pulmonary fibrosis).

          -  Treated for or diagnosed with clinical depression within six months of screening or
             has a history of significant psychiatric illness.

          -  Known history of hypertension or is hypertensive at screening which, in the opinion of
             the Investigator, deems the subject unfit to complete exercise challenge. Hypertension
             at screening is defined as persistent systolic BP &gt;150 mmHg or diastolic BP &gt; 90mmHg.

          -  Known history of gastrointestinal bleeding.

          -  Respiratory tract infection within 2 weeks prior to the first dose of study
             medication.

          -  Asthma exacerbations requiring treatment with oral corticosteroids: any exacerbations
             within 4 weeks of the screening visit or two or more exacerbations within 2 months of
             the screening visit or admittance to hospital for an asthma exacerbation within 6
             months of the screening visit.

          -  History of life-threatening asthma, defined as an asthma episode that required
             intubation and/or was associated with hypercapnoea, respiratory arrest and/or hypoxic
             seizures.

          -  History of alcohol/drug abuse or dependence within 12 months of the study. Abuse of
             alcohol defined as an average weekly intake of &gt;14 drinks/week for men or &gt;7
             drinks/week for women. One drink is equivalent to (12 g alcohol) = 5 ounces (150 ml)
             of wine or 12 ounces (360 ml) of beer or 1.5 ounces (45 ml) of 80 proof distilled
             spirits.

          -  Use of prescription or non-prescription drugs (including CYP 3A4 inhibitors and
             inducers, vitamins and dietary or herbal supplements), from 14 days before screening
             until the follow-up visit, unless in the opinion of the Investigator and sponsor the
             medication will not interfere with the study. Inhaled beta-2 agonists and
             acetaminophen (up to 4 g per day) for the treatment of minor ailments, eg headache,
             are permitted. Hormone replacement therapy (HRT) is also permitted for post-menopausal
             females.

          -  Unable to washout the following protocol defined prohibited medications within the
             defined times:

        Medication Exclusion Period Oral or injectable corticosteroids - No use within 5 weeks of
        the screening visit Inhaled, Intranasal and topical steroids - No use within 4 weeks of the
        screening visit Long acting beta-2 agonists - No use within 48 hours of an exercise
        challenge or dosing or lung function testing Short acting beta-2 agonists - No use within 6
        hours of an exercise challenge or dosing or lung function testing

          -  Following exercise challenge during the screening visit, the subject experiences a
             greater than 40% fall in FEV1 compared to baseline.

          -  Following exercise challenge during the screening visit, the subject is not able to
             recover to at least 20% of baseline FEV1 following administration of short acting
             beta-2 agonists.

          -  Requires rescue medication before all lung function assessments are completed
             following the exercise challenge at screening

          -  Symptomatic with hay fever at screening or predicted to have symptomatic hayfever
             during the time of exercise challenge which, in the opinion of the Investigator, would
             interfere with the outcome of the study.

          -  Participation in a study with a new molecular entity during the previous 3 months or 5
             half-lives (whichever is longer), or participation in a study without a new molecular
             entity during the previous month or 5 half-lives (whichever is longer), prior to the
             first dose of study medication.

          -  Undergoing allergen desensitisation therapy.

          -  There is a risk of subject non-compliance with study procedures.

          -  History of blood donation (500 mL) within 2 months of starting the clinical study.

          -  A screening QTc value of &gt;450msec, PR interval outside the range 120 to 220msec or an
             ECG that is not suitable for QT measurements (e.g. poorly defined termination of the
             T-wave).

          -  Positive pregnancy test for females.

          -  Positive test for hepatitis C antibody or hepatitis B surface antigen.

          -  Positive test for HIV antibodies.

          -  Positive pre-study urine cotinine/ breath carbon monoxide test and or urine drug/urine
             alcohol screen. A minimum list of drugs that will be screened for include
             Amphetamines, Barbiturates, Cocaine, Opiates, Cannabinoids and Benzodiazepines.

          -  Has an affiliation with the Investigative Site. Participation of site personnel, or
             their spouses or children, is not allowed.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>North Dartmouth</city>
        <state>Massachusetts</state>
        <zip>02747</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Orangeburg</city>
        <state>South Carolina</state>
        <zip>29118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79925</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 18, 2008</study_first_submitted>
  <study_first_submitted_qc>December 18, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 22, 2008</study_first_posted>
  <results_first_submitted>July 10, 2017</results_first_submitted>
  <results_first_submitted_qc>August 21, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">September 19, 2017</results_first_posted>
  <disposition_first_submitted>February 5, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>February 5, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">February 10, 2010</disposition_first_posted>
  <last_update_submitted>August 21, 2017</last_update_submitted>
  <last_update_submitted_qc>August 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Asthma, Exercise Induced Asthma, Exercise Induced Bronchospasm</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>112025</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>112025</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>112025</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>112025</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>112025</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>112025</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>112025</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This was a Phase IIa multi-center study conducted in the United States from 02 December 2008 to 15 July 2009.</recruitment_details>
      <pre_assignment_details>A total of 47 participants were randomized in the study who underwent a screening visit of 28 days prior to first dose of study medication.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>P/A/D/B/C</title>
          <description>In this sequence participants received treatment P of oral single dose of aqueous solution of matching placebo on Day 1 of treatment period 1, treatment A of oral single dose of aqueous solution of 10 milligrams (mg) GSK2190915 on Day 1 of treatment period 2, treatment D of oral single dose of aqueous solution of 200 mg GSK2190915 on Day 1 of treatment period 3, treatment B of oral single dose of aqueous solution of 50 mg GSK2190915 on Day 1 of treatment period 4 and treatment C of oral single dose of aqueous solution of 100 mg GSK2190915 on Day 1 of treatment period 5. Each treatment periods were separated by a minimum 7 days washout period. Each treatment period included an exercise challenge at 2, 9.5, and 24 hours post dose and concluded on completion of the assessments following exercise challenge at 24 hours post dose.</description>
        </group>
        <group group_id="P2">
          <title>A/B/P/C/D</title>
          <description>In this sequence participants received treatment A of oral single dose of aqueous solution of 10 mg GSK2190915 on Day 1 of treatment period 1, treatment B of oral single dose of aqueous solution of 50 mg GSK2190915 on Day 1 of treatment period 2, treatment P of oral single dose of aqueous solution of matching placebo on Day 1 of treatment period 3, treatment C of oral single dose of aqueous solution of 100 mg GSK2190915 on Day 1 of treatment period 4 and treatment D of oral single dose of aqueous solution of 200 mg GSK2190915 on Day 1 of treatment period 5. Each treatment periods were separated by a minimum 7 days washout period. Each treatment period included an exercise challenge at 2, 9.5, and 24 hours post dose and concluded on completion of the assessments following exercise challenge at 24 hours post dose.</description>
        </group>
        <group group_id="P3">
          <title>B/C/A/D/P</title>
          <description>In this sequence participants received treatment B of oral single dose of aqueous solution of 50 mg GSK2190915 on Day 1 of treatment period 1, treatment C of oral single dose of aqueous solution of 100 mg GSK2190915 on Day 1 of treatment period 2, treatment A of oral single dose of aqueous solution of 10 mg GSK2190915 on Day 1 of treatment period 3, treatment D of oral single dose of aqueous solution of 200 mg GSK2190915 on Day 1 of treatment period 4, treatment P of oral single dose of aqueous solution of matching placebo on Day 1 of treatment period 5. Each treatment periods were separated by a minimum 7 days washout period. Each treatment period included an exercise challenge at 2, 9.5, and 24 hours post dose and concluded on completion of the assessments following exercise challenge at 24 hours post dose.</description>
        </group>
        <group group_id="P4">
          <title>C/D/B/P/A</title>
          <description>In this sequence participants received treatment C of oral single dose of aqueous solution of 100 mg GSK2190915 on Day 1 of treatment period 1, treatment D of oral single dose of aqueous solution of 200 mg GSK2190915 on Day 1 of treatment period 2, treatment B of oral single dose of aqueous solution of 50 mg GSK2190915 on Day 1 of treatment period 3, treatment P of oral single dose of aqueous solution of matching placebo on Day 1 of treatment period 4, treatment A of oral single dose of aqueous solution of 10 mg GSK2190915 on Day 1 of treatment period 5. Each treatment periods were separated by a minimum 7 days washout period. Each treatment period included an exercise challenge at 2, 9.5, and 24 hours post dose and concluded on completion of the assessments following exercise challenge at 24 hours post dose.</description>
        </group>
        <group group_id="P5">
          <title>D/P/C/A/B</title>
          <description>In this sequence participants received treatment D of oral single dose of aqueous solution of 200 mg GSK2190915 on Day 1 of treatment period 1, treatment P of oral single dose of aqueous solution of matching placebo on Day 1 of treatment period 2, treatment C of oral single dose of aqueous solution of 100 mg GSK2190915 on Day 1 of treatment period 3, treatment A of oral single dose of aqueous solution of 10 mg GSK2190915 on Day 1 of treatment period 4, treatment B of oral single dose of aqueous solution of 50 mg GSK2190915 on Day 1 of treatment period 5. Each treatment periods were separated by a minimum 7 days washout period. Each treatment period included an exercise challenge at 2, 9.5, and 24 hours post dose and concluded on completion of the assessments following exercise challenge at 24 hours post dose.</description>
        </group>
        <group group_id="P6">
          <title>C/B/D/A/P</title>
          <description>In this sequence participants received treatment C of oral single dose of aqueous solution of 100 mg GSK2190915 on Day 1 of treatment period 1, treatment B of oral single dose of aqueous solution of 50 mg GSK2190915 on Day 1 of treatment period 2, treatment D of oral single dose of aqueous solution of 200 mg GSK2190915 on Day 1 of treatment period 3, treatment A of oral single dose of aqueous solution of 10 mg GSK2190915 on Day 1 of treatment period 4, treatment P of oral single dose of aqueous solution of matching placebo on Day 1 of treatment period 5. Each treatment periods were separated by a minimum 7 days washout period. Each treatment period included an exercise challenge at 2, 9.5, and 24 hours post dose and concluded on completion of the assessments following exercise challenge at 24 hours post dose.</description>
        </group>
        <group group_id="P7">
          <title>D/C/P/B/A</title>
          <description>In this sequence participants received treatment D of oral single dose of aqueous solution of 200 mg GSK2190915 on Day 1 of treatment period 1, treatment C of oral single dose of aqueous solution of 100 mg GSK2190915 on Day 1 of treatment period 2, treatment P of oral single dose of aqueous solution of matching placebo on Day 1 of treatment period 3, treatment B of oral single dose of aqueous solution of 50 mg GSK2190915 on Day 1 of treatment period 4, treatment A of oral single dose of aqueous solution of 10 mg GSK2190915 on Day 1 of treatment period 5. Each treatment periods were separated by a minimum 7 days washout period. Each treatment period included an exercise challenge at 2, 9.5, and 24 hours post dose and concluded on completion of the assessments following exercise challenge at 24 hours post dose.</description>
        </group>
        <group group_id="P8">
          <title>P/D/A/C/B</title>
          <description>In this sequence participants received treatment P of oral single dose of aqueous solution of matching placebo on Day 1 of treatment period 1, treatment D of oral single dose of aqueous solution of 200 mg GSK2190915 on Day 1 of treatment period 2, treatment A of oral single dose of aqueous solution of 10 mg GSK2190915 on Day 1 of treatment period 3, treatment C of oral single dose of aqueous solution of 100 mg GSK2190915 on Day 1 of treatment period 4, treatment B of oral single dose of aqueous solution of 50 mg GSK2190915 on Day 1 of treatment period 5. Each treatment periods were separated by a minimum 7 days washout period. Each treatment period included an exercise challenge at 2, 9.5, and 24 hours post dose and concluded on completion of the assessments following exercise challenge at 24 hours post dose.</description>
        </group>
        <group group_id="P9">
          <title>A/P/B/D/C</title>
          <description>In this sequence participants received treatment A of oral single dose of aqueous solution of 10 mg GSK2190915 on Day 1 of treatment period 1, treatment P of oral single dose of aqueous solution of matching placebo on Day 1 of treatment period 2, treatment B of oral single dose of aqueous solution of 50 mg GSK2190915 on Day 1 of treatment period 3, treatment D of oral single dose of aqueous solution of 200 mg GSK2190915 on Day 1 of treatment period 4, treatment C of oral single dose of aqueous solution of 100 mg GSK2190915 on Day 1 of treatment period 5. Each treatment periods were separated by a minimum 7 days washout period. Each treatment period included an exercise challenge at 2, 9.5, and 24 hours post dose and concluded on completion of the assessments following exercise challenge at 24 hours post dose.</description>
        </group>
        <group group_id="P10">
          <title>B/A/C/P/D</title>
          <description>In this sequence participants received treatment B of oral single dose of aqueous solution of 50 mg GSK2190915 on Day 1 of treatment period 1, treatment A of oral single dose of aqueous solution of 10 mg GSK2190915 on Day 1 of treatment period 2, treatment C of oral single dose of aqueous solution of 100 mg GSK2190915 on Day 1 of treatment period 3, treatment P of oral single dose of aqueous solution of matching placebo on Day 1 of treatment period 4, treatment D of oral single dose of aqueous solution of 200 mg GSK2190915 on Day 1 of treatment period 5. Each treatment periods were separated by a minimum 7 days washout period. Each treatment period included an exercise challenge at 2, 9.5, and 24 hours post dose and concluded on completion of the assessments following exercise challenge at 24 hours post dose.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Treatment Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="5"/>
                <participants group_id="P7" count="5"/>
                <participants group_id="P8" count="5"/>
                <participants group_id="P9" count="4"/>
                <participants group_id="P10" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="5"/>
                <participants group_id="P7" count="5"/>
                <participants group_id="P8" count="5"/>
                <participants group_id="P9" count="4"/>
                <participants group_id="P10" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout Period 1 (7 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="5"/>
                <participants group_id="P7" count="5"/>
                <participants group_id="P8" count="5"/>
                <participants group_id="P9" count="4"/>
                <participants group_id="P10" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="5"/>
                <participants group_id="P7" count="5"/>
                <participants group_id="P8" count="5"/>
                <participants group_id="P9" count="4"/>
                <participants group_id="P10" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Treatment Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="5"/>
                <participants group_id="P7" count="5"/>
                <participants group_id="P8" count="5"/>
                <participants group_id="P9" count="4"/>
                <participants group_id="P10" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="5"/>
                <participants group_id="P7" count="5"/>
                <participants group_id="P8" count="5"/>
                <participants group_id="P9" count="4"/>
                <participants group_id="P10" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout Period 2 (7 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="5"/>
                <participants group_id="P7" count="5"/>
                <participants group_id="P8" count="5"/>
                <participants group_id="P9" count="4"/>
                <participants group_id="P10" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="5"/>
                <participants group_id="P7" count="5"/>
                <participants group_id="P8" count="5"/>
                <participants group_id="P9" count="4"/>
                <participants group_id="P10" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Treatment Period 3</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="5"/>
                <participants group_id="P7" count="5"/>
                <participants group_id="P8" count="5"/>
                <participants group_id="P9" count="4"/>
                <participants group_id="P10" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="5"/>
                <participants group_id="P7" count="5"/>
                <participants group_id="P8" count="5"/>
                <participants group_id="P9" count="4"/>
                <participants group_id="P10" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout Period 3 (7 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="5"/>
                <participants group_id="P7" count="5"/>
                <participants group_id="P8" count="5"/>
                <participants group_id="P9" count="4"/>
                <participants group_id="P10" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="5"/>
                <participants group_id="P8" count="5"/>
                <participants group_id="P9" count="4"/>
                <participants group_id="P10" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Treatment Period 4</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="5"/>
                <participants group_id="P8" count="5"/>
                <participants group_id="P9" count="4"/>
                <participants group_id="P10" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="5"/>
                <participants group_id="P8" count="5"/>
                <participants group_id="P9" count="4"/>
                <participants group_id="P10" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout Period 4 (7 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="5"/>
                <participants group_id="P8" count="5"/>
                <participants group_id="P9" count="4"/>
                <participants group_id="P10" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="5"/>
                <participants group_id="P8" count="5"/>
                <participants group_id="P9" count="4"/>
                <participants group_id="P10" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Treatment Period 5</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="5"/>
                <participants group_id="P8" count="5"/>
                <participants group_id="P9" count="4"/>
                <participants group_id="P10" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="5"/>
                <participants group_id="P8" count="5"/>
                <participants group_id="P9" count="4"/>
                <participants group_id="P10" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Total</title>
          <description>Eligible participants completed five treatment periods (single dose 10 mg, 50 mg, 100 mg, 200 mg GSK2190915 oral solution, compared to placebo control which was administered on Day 1 of each treatment period). Each treatment period lasted 2 days, with a minimum 7 day washout period between each treatment periods.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="47"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.4" spread="8.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximal Percentage Change From Pre-exercise Baseline Forced Expiratory Volume in 1 Second (FEV1) to the Minimum FEV1 Collected Within 60 Minutes Following the Exercise Challenge at 24 Hours Post Dose</title>
        <description>FEV1 was recorded in triplicate, with participant encouraged to inhale fully despite any presence of chest tightness. For FEV1, a pre-challenge Baseline was defined for each challenge time point as maximum of triplicate measurements performed prior to challenge. The maximal percentage change within 60 minutes following exercise challenge was derived by taking minimum (i.e., most negative) percentage change in FEV1 over 5, 10, 15, 30, 45 and 60 minutes post challenge. Percent change FEV1 = 100*(FEV1  Pre-challenge FEV1)/ Pre-challenge FEV1. If the exercise challenge was not completed successfully (i.e. heart rate maintained at &gt;=80% of the predicted value for 6 minutes), FEV1 maximal percent change (0-60)was set to be missing. Analysis was performed using a mixed effects model, including period, treatment and covariates for predose FEV1. Estimates and 95% confidence intervals for treatment difference between each active dose and placebo for each challenge time point were calculated.</description>
        <time_frame>Baseline (pre dose) and 60 minutes following the exercise challenge at 24 hours post dose of each treatment period.</time_frame>
        <population>The Efficacy Population was defined as all participants who received at least one dose of study medication and are not major protocol violators.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Eligible participants received Placebo matching GSK2190915 oral solution which was administered with 100 milliliter (mL) of water on Day 1 of each treatment period.</description>
          </group>
          <group group_id="O2">
            <title>GSK2190915 10 mg</title>
            <description>Eligible participants received single dose 10 mg GSK2190915 oral solution which was administered with 100 mL of water on Day 1 of each treatment period.</description>
          </group>
          <group group_id="O3">
            <title>GSK2190915 50 mg</title>
            <description>Eligible participants received single dose 50 mg GSK2190915 oral solution which was administered with 100 mL of water on Day 1 of each treatment period.</description>
          </group>
          <group group_id="O4">
            <title>GSK2190915 100 mg</title>
            <description>Eligible participants received single dose 100 mg GSK2190915 oral solution which was administered with 100 mL of water on Day 1 of each treatment period.</description>
          </group>
          <group group_id="O5">
            <title>GSK2190915 200 mg</title>
            <description>Eligible participants received single dose 200 mg GSK2190915 oral solution which was administered with 100 mL of water on Day 1 of each treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximal Percentage Change From Pre-exercise Baseline Forced Expiratory Volume in 1 Second (FEV1) to the Minimum FEV1 Collected Within 60 Minutes Following the Exercise Challenge at 24 Hours Post Dose</title>
          <description>FEV1 was recorded in triplicate, with participant encouraged to inhale fully despite any presence of chest tightness. For FEV1, a pre-challenge Baseline was defined for each challenge time point as maximum of triplicate measurements performed prior to challenge. The maximal percentage change within 60 minutes following exercise challenge was derived by taking minimum (i.e., most negative) percentage change in FEV1 over 5, 10, 15, 30, 45 and 60 minutes post challenge. Percent change FEV1 = 100*(FEV1  Pre-challenge FEV1)/ Pre-challenge FEV1. If the exercise challenge was not completed successfully (i.e. heart rate maintained at &gt;=80% of the predicted value for 6 minutes), FEV1 maximal percent change (0-60)was set to be missing. Analysis was performed using a mixed effects model, including period, treatment and covariates for predose FEV1. Estimates and 95% confidence intervals for treatment difference between each active dose and placebo for each challenge time point were calculated.</description>
          <population>The Efficacy Population was defined as all participants who received at least one dose of study medication and are not major protocol violators.</population>
          <units>Percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="46"/>
                <count group_id="O4" value="45"/>
                <count group_id="O5" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.61" spread="1.326"/>
                    <measurement group_id="O2" value="-6.33" spread="1.314"/>
                    <measurement group_id="O3" value="-7.09" spread="1.307"/>
                    <measurement group_id="O4" value="-7.28" spread="1.314"/>
                    <measurement group_id="O5" value="-5.09" spread="1.315"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>1.29</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.440</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.56</ci_lower_limit>
            <ci_upper_limit>4.13</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.53</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.440</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.32</ci_lower_limit>
            <ci_upper_limit>3.37</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.33</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.441</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.52</ci_lower_limit>
            <ci_upper_limit>3.18</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>2.53</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.438</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.31</ci_lower_limit>
            <ci_upper_limit>5.37</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximal Percentage Change From Pre-exercise Baseline FEV1 to the Minimum FEV1 Collected Within 60 Minutes Following the Exercise Challenge at 2 and 9.5 Hours Post Dose</title>
        <description>FEV1 was recorded in triplicate, with participant encouraged to inhale fully despite any presence of chest tightness. For FEV1, a pre-challenge Baseline was defined for each challenge time point as maximum of triplicate measurements performed prior to challenge. The maximal percentage change within 60 minutes following exercise challenge was derived by taking minimum percentage change in FEV1 over 5, 10, 15, 30, 45 and 60 minutes post challenge. Percent change FEV1 = 100*(FEV1  Pre-challenge FEV1)/ Pre-challenge FEV1. If the exercise challenge was not completed successfully (i.e. heart rate maintained at &gt;=80% of the predicted value for 6 minutes), the FEV1 maximal percent change (0-60)was set to be missing. Analysis was performed using a mixed effects model, including period, treatment and covariates for predose FEV1. Estimates and 95% confidence intervals for treatment difference between each active dose and placebo for each challenge time point were calculated.</description>
        <time_frame>Baseline (pre dose) and 60 minutes following the exercise challenge at 2 and 9.5 hours post dose of each treatment period.</time_frame>
        <population>Efficacy Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Eligible participants received Placebo matching GSK2190915 oral solution which was administered with 100 mL of water on Day 1 of each treatment period.</description>
          </group>
          <group group_id="O2">
            <title>GSK2190915 10 mg</title>
            <description>Eligible participants received single dose 10 mg GSK2190915 oral solution which was administered with 100 mL of water on Day 1 of each treatment period.</description>
          </group>
          <group group_id="O3">
            <title>GSK2190915 50 mg</title>
            <description>Eligible participants received single dose 50 mg GSK2190915 oral solution which was administered with 100 mL of water on Day 1 of each treatment period.</description>
          </group>
          <group group_id="O4">
            <title>GSK2190915 100 mg</title>
            <description>Eligible participants received single dose 100 mg GSK2190915 oral solution which was administered with 100 mL of water on Day 1 of each treatment period.</description>
          </group>
          <group group_id="O5">
            <title>GSK2190915 200 mg</title>
            <description>Eligible participants received single dose 200 mg GSK2190915 oral solution which was administered with 100 mL of water on Day 1 of each treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximal Percentage Change From Pre-exercise Baseline FEV1 to the Minimum FEV1 Collected Within 60 Minutes Following the Exercise Challenge at 2 and 9.5 Hours Post Dose</title>
          <description>FEV1 was recorded in triplicate, with participant encouraged to inhale fully despite any presence of chest tightness. For FEV1, a pre-challenge Baseline was defined for each challenge time point as maximum of triplicate measurements performed prior to challenge. The maximal percentage change within 60 minutes following exercise challenge was derived by taking minimum percentage change in FEV1 over 5, 10, 15, 30, 45 and 60 minutes post challenge. Percent change FEV1 = 100*(FEV1  Pre-challenge FEV1)/ Pre-challenge FEV1. If the exercise challenge was not completed successfully (i.e. heart rate maintained at &gt;=80% of the predicted value for 6 minutes), the FEV1 maximal percent change (0-60)was set to be missing. Analysis was performed using a mixed effects model, including period, treatment and covariates for predose FEV1. Estimates and 95% confidence intervals for treatment difference between each active dose and placebo for each challenge time point were calculated.</description>
          <population>Efficacy Population.</population>
          <units>Percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="46"/>
                <count group_id="O4" value="45"/>
                <count group_id="O5" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>2 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.55" spread="1.437"/>
                    <measurement group_id="O2" value="-13.04" spread="1.424"/>
                    <measurement group_id="O3" value="-12.95" spread="1.416"/>
                    <measurement group_id="O4" value="-12.76" spread="1.424"/>
                    <measurement group_id="O5" value="-9.25" spread="1.425"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9.5 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.45" spread="1.222"/>
                    <measurement group_id="O2" value="-8.33" spread="1.212"/>
                    <measurement group_id="O3" value="-7.69" spread="1.206"/>
                    <measurement group_id="O4" value="-4.96" spread="1.213"/>
                    <measurement group_id="O5" value="-6.18" spread="1.213"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>2 Hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>2.52</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.638</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.72</ci_lower_limit>
            <ci_upper_limit>5.75</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>9.5 Hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.12</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.247</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.34</ci_lower_limit>
            <ci_upper_limit>2.58</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>2 Hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>2.60</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.637</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.64</ci_lower_limit>
            <ci_upper_limit>5.84</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>9.5 Hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.76</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.247</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.70</ci_lower_limit>
            <ci_upper_limit>3.22</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>2 Hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>2.79</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.639</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.45</ci_lower_limit>
            <ci_upper_limit>6.03</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>9.5 Hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>3.49</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.248</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.02</ci_lower_limit>
            <ci_upper_limit>5.95</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>2 Hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>6.30</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.637</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.06</ci_lower_limit>
            <ci_upper_limit>9.54</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>9.5 Hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>2.27</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.245</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.19</ci_lower_limit>
            <ci_upper_limit>4.73</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Weighted Mean (WM) for FEV1 Percentage Change From Baseline Recorded During 0 to 60 Minutes Following Exercise Challenge (FEV1 WM0-60)</title>
        <description>FEV1 was recorded in triplicate, with participant encouraged to inhale fully despite any presence of chest tightness. For FEV1, a pre-challenge Baseline was defined for each challenge time point as maximum of triplicate measurements performed prior to challenge.Weighted mean FEV1 percentage change recorded during 0-60 minutes post challenge was determined for each challenge, by dividing area under curve (AUC) for percent change from Baseline FEV1 measurements at 5, 10, 15, 30, 45 and 60 minutes post challenge by time interval. Actual times were used to determine time interval where available; otherwise planned relative time was used. If one or more FEV1 values were missing, AUC was calculated over time interval of available values. If intermittent values were missing over a participants profile,it was assumed to be linear between 2 available values for calculation of AUC. Analysis was performed using a mixed effects model, including period, treatment and covariates for predose FEV1.</description>
        <time_frame>Baseline (pre dose) and 0 to 60 minutes following exercise challenge at 2, 9.5 and 24 hours post dose of each treatment period.</time_frame>
        <population>Efficacy Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Eligible participants received Placebo matching GSK2190915 oral solution which was administered with 100 mL of water on Day 1 of each treatment period.</description>
          </group>
          <group group_id="O2">
            <title>GSK2190915 10 mg</title>
            <description>Eligible participants received single dose 10 mg GSK2190915 oral solution which was administered with 100 mL of water on Day 1 of each treatment period.</description>
          </group>
          <group group_id="O3">
            <title>GSK2190915 50 mg</title>
            <description>Eligible participants received single dose 50 mg GSK2190915 oral solution which was administered with 100 mL of water on Day 1 of each treatment period.</description>
          </group>
          <group group_id="O4">
            <title>GSK2190915 100 mg</title>
            <description>Eligible participants received single dose 100 mg GSK2190915 oral solution which was administered with 100 mL of water on Day 1 of each treatment period.</description>
          </group>
          <group group_id="O5">
            <title>GSK2190915 200 mg</title>
            <description>Eligible participants received single dose 200 mg GSK2190915 oral solution which was administered with 100 mL of water on Day 1 of each treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Weighted Mean (WM) for FEV1 Percentage Change From Baseline Recorded During 0 to 60 Minutes Following Exercise Challenge (FEV1 WM0-60)</title>
          <description>FEV1 was recorded in triplicate, with participant encouraged to inhale fully despite any presence of chest tightness. For FEV1, a pre-challenge Baseline was defined for each challenge time point as maximum of triplicate measurements performed prior to challenge.Weighted mean FEV1 percentage change recorded during 0-60 minutes post challenge was determined for each challenge, by dividing area under curve (AUC) for percent change from Baseline FEV1 measurements at 5, 10, 15, 30, 45 and 60 minutes post challenge by time interval. Actual times were used to determine time interval where available; otherwise planned relative time was used. If one or more FEV1 values were missing, AUC was calculated over time interval of available values. If intermittent values were missing over a participants profile,it was assumed to be linear between 2 available values for calculation of AUC. Analysis was performed using a mixed effects model, including period, treatment and covariates for predose FEV1.</description>
          <population>Efficacy Population.</population>
          <units>Percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="46"/>
                <count group_id="O4" value="45"/>
                <count group_id="O5" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>2 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.20" spread="0.936"/>
                    <measurement group_id="O2" value="-4.26" spread="0.926"/>
                    <measurement group_id="O3" value="-4.08" spread="0.920"/>
                    <measurement group_id="O4" value="-3.69" spread="0.926"/>
                    <measurement group_id="O5" value="-2.04" spread="0.927"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9.5 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.43" spread="0.757"/>
                    <measurement group_id="O2" value="-2.36" spread="0.750"/>
                    <measurement group_id="O3" value="-1.21" spread="0.745"/>
                    <measurement group_id="O4" value="0.87" spread="0.750"/>
                    <measurement group_id="O5" value="-0.32" spread="0.750"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.25" spread="0.755"/>
                    <measurement group_id="O2" value="0.65" spread="0.747"/>
                    <measurement group_id="O3" value="-0.08" spread="0.742"/>
                    <measurement group_id="O4" value="-0.35" spread="0.747"/>
                    <measurement group_id="O5" value="1.46" spread="0.748"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>2 Hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.94</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.170</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.37</ci_lower_limit>
            <ci_upper_limit>3.25</ci_upper_limit>
            <estimate_desc>Estimates and 95% confidence intervals for treatment difference between each active dose and placebo for each challenge time point were calculated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>9.5 Hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.07</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.878</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.66</ci_lower_limit>
            <ci_upper_limit>1.80</ci_upper_limit>
            <estimate_desc>Estimates and 95% confidence intervals for treatment difference between each active dose and placebo for each challenge time point were calculated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>24 Hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.90</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.873</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.82</ci_lower_limit>
            <ci_upper_limit>2.63</ci_upper_limit>
            <estimate_desc>Estimates and 95% confidence intervals for treatment difference between each active dose and placebo for each challenge time point were calculated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>2 Hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>1.12</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.169</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.19</ci_lower_limit>
            <ci_upper_limit>3.43</ci_upper_limit>
            <estimate_desc>Estimates and 95% confidence intervals for treatment difference between each active dose and placebo for each challenge time point were calculated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>9.5 Hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>1.22</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.878</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.51</ci_lower_limit>
            <ci_upper_limit>2.95</ci_upper_limit>
            <estimate_desc>Estimates and 95% confidence intervals for treatment difference between each active dose and placebo for each challenge time point were calculated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>24 Hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.18</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.873</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.55</ci_lower_limit>
            <ci_upper_limit>1.90</ci_upper_limit>
            <estimate_desc>Estimates and 95% confidence intervals for treatment difference between each active dose and placebo for each challenge time point were calculated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>2 Hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>1.51</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.171</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.80</ci_lower_limit>
            <ci_upper_limit>3.82</ci_upper_limit>
            <estimate_desc>Estimates and 95% confidence intervals for treatment difference between each active dose and placebo for each challenge time point were calculated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>9.5 Hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>3.30</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.879</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.57</ci_lower_limit>
            <ci_upper_limit>5.03</ci_upper_limit>
            <estimate_desc>Estimates and 95% confidence intervals for treatment difference between each active dose and placebo for each challenge time point were calculated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>24 Hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.10</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.874</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.83</ci_lower_limit>
            <ci_upper_limit>1.62</ci_upper_limit>
            <estimate_desc>Estimates and 95% confidence intervals for treatment difference between each active dose and placebo for each challenge time point were calculated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>2 Hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>3.17</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.169</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.86</ci_lower_limit>
            <ci_upper_limit>5.48</ci_upper_limit>
            <estimate_desc>Estimates and 95% confidence intervals for treatment difference between each active dose and placebo for each challenge time point were calculated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>9.5 Hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>2.11</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.877</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.38</ci_lower_limit>
            <ci_upper_limit>3.84</ci_upper_limit>
            <estimate_desc>Estimates and 95% confidence intervals for treatment difference between each active dose and placebo for each challenge time point were calculated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>24 Hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>1.72</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.872</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.00</ci_lower_limit>
            <ci_upper_limit>3.44</ci_upper_limit>
            <estimate_desc>Estimates and 95% confidence intervals for treatment difference between each active dose and placebo for each challenge time point were calculated.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to FEV1 Recovery to Within 5 Percent of Baseline Following Exercise Challenge</title>
        <description>The time from maximal percentage change in FEV1 to recovery to within 5% of pre challenge Baseline (in minutes) was derived using actual sampling times. Time to FEV1 recovery= [SAS date/time of recovery(a) FEV1  SAS date/time of FEV1 Maximum % Change0-60] / 60, where &quot;a&quot; is earliest recorded FEV1 either above pre-challenge Baseline or within 5% below pre challenge Baseline. Any unscheduled FEV1 measurements taken after last scheduled post challenge measurement was considered when deriving this endpoint. A corresponding censoring variable was derived for analysis to indicate whether recovery to within 5% of pre-challenge Baseline was achieved. The censoring variable was set to 1 if recovery to within 5% of Baseline was achieved. If recovery was not evident from data collected, time to recovery was calculated using the date/time of the last available post challenge FEV1 assessment and censoring variable was set to zero. Analysis was performed using a Cox proportional hazards model.</description>
        <time_frame>0 to 60 minutes following exercise challenge at 2, 9.5 and 24 hours post dose of each treatment period</time_frame>
        <population>Efficacy Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Eligible participants received Placebo matching GSK2190915 oral solution which was administered with 100 mL of water on Day 1 of each treatment period.</description>
          </group>
          <group group_id="O2">
            <title>GSK2190915 10 mg</title>
            <description>Eligible participants received single dose 10 mg GSK2190915 oral solution which was administered with 100 mL of water on Day 1 of each treatment period.</description>
          </group>
          <group group_id="O3">
            <title>GSK2190915 50 mg</title>
            <description>Eligible participants received single dose 50 mg GSK2190915 oral solution which was administered with 100 mL of water on Day 1 of each treatment period.</description>
          </group>
          <group group_id="O4">
            <title>GSK2190915 100 mg</title>
            <description>Eligible participants received single dose 100 mg GSK2190915 oral solution which was administered with 100 mL of water on Day 1 of each treatment period.</description>
          </group>
          <group group_id="O5">
            <title>GSK2190915 200 mg</title>
            <description>Eligible participants received single dose 200 mg GSK2190915 oral solution which was administered with 100 mL of water on Day 1 of each treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to FEV1 Recovery to Within 5 Percent of Baseline Following Exercise Challenge</title>
          <description>The time from maximal percentage change in FEV1 to recovery to within 5% of pre challenge Baseline (in minutes) was derived using actual sampling times. Time to FEV1 recovery= [SAS date/time of recovery(a) FEV1  SAS date/time of FEV1 Maximum % Change0-60] / 60, where &quot;a&quot; is earliest recorded FEV1 either above pre-challenge Baseline or within 5% below pre challenge Baseline. Any unscheduled FEV1 measurements taken after last scheduled post challenge measurement was considered when deriving this endpoint. A corresponding censoring variable was derived for analysis to indicate whether recovery to within 5% of pre-challenge Baseline was achieved. The censoring variable was set to 1 if recovery to within 5% of Baseline was achieved. If recovery was not evident from data collected, time to recovery was calculated using the date/time of the last available post challenge FEV1 assessment and censoring variable was set to zero. Analysis was performed using a Cox proportional hazards model.</description>
          <population>Efficacy Population.</population>
          <units>Minutes</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="46"/>
                <count group_id="O4" value="45"/>
                <count group_id="O5" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>2 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.5" lower_limit="15.0" upper_limit="36.0"/>
                    <measurement group_id="O2" value="15.0" lower_limit="10.0" upper_limit="30.0"/>
                    <measurement group_id="O3" value="18.0" lower_limit="5.0" upper_limit="35.0"/>
                    <measurement group_id="O4" value="10.0" lower_limit="5.0" upper_limit="16.0"/>
                    <measurement group_id="O5" value="5.0" lower_limit="0.0" upper_limit="12.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9.5 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" lower_limit="0.0" upper_limit="18.0"/>
                    <measurement group_id="O2" value="9.0" lower_limit="0.0" upper_limit="25.0"/>
                    <measurement group_id="O3" value="5.0" lower_limit="0.0" upper_limit="10.0"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="5.0"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" lower_limit="0.0" upper_limit="16.0"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="5.0"/>
                    <measurement group_id="O3" value="2.5" lower_limit="0.0" upper_limit="6.0"/>
                    <measurement group_id="O4" value="5.0" lower_limit="0.0" upper_limit="5.0"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>2 Hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.25</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.71</ci_lower_limit>
            <ci_upper_limit>2.21</ci_upper_limit>
            <estimate_desc>Hazard ratio = ratio of likelihood of recovery at any time on active treatment vs placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>9.5 Hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.10</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.59</ci_lower_limit>
            <ci_upper_limit>2.06</ci_upper_limit>
            <estimate_desc>Hazard ratio = ratio of likelihood of recovery at any time on active treatment vs placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>24 Hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.78</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.93</ci_lower_limit>
            <ci_upper_limit>3.43</ci_upper_limit>
            <estimate_desc>Hazard ratio = ratio of likelihood of recovery at any time on active treatment vs placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>2 Hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.42</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.81</ci_lower_limit>
            <ci_upper_limit>2.48</ci_upper_limit>
            <estimate_desc>Hazard ratio = ratio of likelihood of recovery at any time on active treatment vs placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>9.5 Hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.93</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.01</ci_lower_limit>
            <ci_upper_limit>3.66</ci_upper_limit>
            <estimate_desc>Hazard ratio = ratio of likelihood of recovery at any time on active treatment vs placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>24 Hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.67</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.86</ci_lower_limit>
            <ci_upper_limit>3.25</ci_upper_limit>
            <estimate_desc>Hazard ratio = ratio of likelihood of recovery at any time on active treatment vs placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>2 Hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>2.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.19</ci_lower_limit>
            <ci_upper_limit>3.69</ci_upper_limit>
            <estimate_desc>Hazard ratio = ratio of likelihood of recovery at any time on active treatment vs placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>9.5 Hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>5.49</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.75</ci_lower_limit>
            <ci_upper_limit>10.94</ci_upper_limit>
            <estimate_desc>Hazard ratio = ratio of likelihood of recovery at any time on active treatment vs placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>24 Hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.91</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.00</ci_lower_limit>
            <ci_upper_limit>3.64</ci_upper_limit>
            <estimate_desc>Hazard ratio = ratio of likelihood of recovery at any time on active treatment vs placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>2 Hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>3.60</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.00</ci_lower_limit>
            <ci_upper_limit>6.48</ci_upper_limit>
            <estimate_desc>Hazard ratio = ratio of likelihood of recovery at any time on active treatment vs placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>9.5 Hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>2.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.07</ci_lower_limit>
            <ci_upper_limit>3.87</ci_upper_limit>
            <estimate_desc>Hazard ratio = ratio of likelihood of recovery at any time on active treatment vs placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>24 Hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>6.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.90</ci_lower_limit>
            <ci_upper_limit>12.71</ci_upper_limit>
            <estimate_desc>Hazard ratio = ratio of likelihood of recovery at any time on active treatment vs placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Using a Short Acting Beta-2 Agonist (Rescue Medication) During 0 to 90 Minutes Following Exercise Challenge</title>
        <description>Rescue medication was provided to participants at any time and it was strongly recommended for participants with a FEV1 decrease of at least 40% following exercise challenge compared to Baseline. Rescue medication was administered 0 to 90 minutes post exercise challenge. Statistical analysis was supposed to be performed using logistic regression, however, the data was too sparse to permit any formal statistical analysis.</description>
        <time_frame>0 to 90 minutes following exercise challenge of each treatment period</time_frame>
        <population>Efficacy Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Eligible participants received Placebo matching GSK2190915 oral solution which was administered with 100 mL of water on Day 1 of each treatment period.</description>
          </group>
          <group group_id="O2">
            <title>GSK2190915 10 mg</title>
            <description>Eligible participants received single dose 10 mg GSK2190915 oral solution which was administered with 100 mL of water on Day 1 of each treatment period.</description>
          </group>
          <group group_id="O3">
            <title>GSK2190915 50 mg</title>
            <description>Eligible participants received single dose 50 mg GSK2190915 oral solution which was administered with 100 mL of water on Day 1 of each treatment period.</description>
          </group>
          <group group_id="O4">
            <title>GSK2190915 100 mg</title>
            <description>Eligible participants received single dose 100 mg GSK2190915 oral solution which was administered with 100 mL of water on Day 1 of each treatment period.</description>
          </group>
          <group group_id="O5">
            <title>GSK2190915 200 mg</title>
            <description>Eligible participants received single dose 200 mg GSK2190915 oral solution which was administered with 100 mL of water on Day 1 of each treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Using a Short Acting Beta-2 Agonist (Rescue Medication) During 0 to 90 Minutes Following Exercise Challenge</title>
          <description>Rescue medication was provided to participants at any time and it was strongly recommended for participants with a FEV1 decrease of at least 40% following exercise challenge compared to Baseline. Rescue medication was administered 0 to 90 minutes post exercise challenge. Statistical analysis was supposed to be performed using logistic regression, however, the data was too sparse to permit any formal statistical analysis.</description>
          <population>Efficacy Population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="46"/>
                <count group_id="O4" value="45"/>
                <count group_id="O5" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>2 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9.5 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assessment of Vital Signs: Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)</title>
        <description>All participants rested for at least 10 minutes in the supine position prior to vital signs recordings. Vital signs Baseline values for SBP and DBP for each treatment period were calculated using the mean value of triplicate pre dose readings. Triplicate readings were taken at least five minutes apart. Assessment was performed at pre dose, 2 hours, 9.5 hours and 24 hours prior to exercise challenge.</description>
        <time_frame>Pre dose, 2 hours, 9.5 hours and 24 hours prior to exercise challenge of treatment period</time_frame>
        <population>All Subjects Population was defined as all participants who received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Eligible participants received Placebo matching GSK2190915 oral solution which was administered with 100 mL of water on Day 1 of each treatment period.</description>
          </group>
          <group group_id="O2">
            <title>GSK2190915 10 mg</title>
            <description>Eligible participants received single dose 10 mg GSK2190915 oral solution which was administered with 100 mL of water on Day 1 of each treatment period.</description>
          </group>
          <group group_id="O3">
            <title>GSK2190915 50 mg</title>
            <description>Eligible participants received single dose 50 mg GSK2190915 oral solution which was administered with 100 mL of water on Day 1 of each treatment period.</description>
          </group>
          <group group_id="O4">
            <title>GSK2190915 100 mg</title>
            <description>Eligible participants received single dose 100 mg GSK2190915 oral solution which was administered with 100 mL of water on Day 1 of each treatment period.</description>
          </group>
          <group group_id="O5">
            <title>GSK2190915 200 mg</title>
            <description>Eligible participants received single dose 200 mg GSK2190915 oral solution which was administered with 100 mL of water on Day 1 of each treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Vital Signs: Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)</title>
          <description>All participants rested for at least 10 minutes in the supine position prior to vital signs recordings. Vital signs Baseline values for SBP and DBP for each treatment period were calculated using the mean value of triplicate pre dose readings. Triplicate readings were taken at least five minutes apart. Assessment was performed at pre dose, 2 hours, 9.5 hours and 24 hours prior to exercise challenge.</description>
          <population>All Subjects Population was defined as all participants who received at least one dose of study medication.</population>
          <units>Millimeters of mercury (mmHg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="47"/>
                <count group_id="O4" value="45"/>
                <count group_id="O5" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SBP, Mean Pre Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="118.8" spread="10.21"/>
                    <measurement group_id="O2" value="117.2" spread="10.45"/>
                    <measurement group_id="O3" value="117.6" spread="11.53"/>
                    <measurement group_id="O4" value="117.4" spread="11.49"/>
                    <measurement group_id="O5" value="118.1" spread="11.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, 2 Hours, Pre Exercise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120.1" spread="10.50"/>
                    <measurement group_id="O2" value="119.8" spread="11.50"/>
                    <measurement group_id="O3" value="119.1" spread="10.48"/>
                    <measurement group_id="O4" value="119.4" spread="10.42"/>
                    <measurement group_id="O5" value="120.3" spread="11.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, 9.5 Hours, Pre Exercise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="119.4" spread="10.50"/>
                    <measurement group_id="O2" value="117.0" spread="8.69"/>
                    <measurement group_id="O3" value="120.5" spread="11.37"/>
                    <measurement group_id="O4" value="119.7" spread="10.58"/>
                    <measurement group_id="O5" value="118.4" spread="11.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, 24 Hours, Pre Exercise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="117.2" spread="11.62"/>
                    <measurement group_id="O2" value="116.9" spread="10.73"/>
                    <measurement group_id="O3" value="117.4" spread="9.93"/>
                    <measurement group_id="O4" value="117.5" spread="11.00"/>
                    <measurement group_id="O5" value="119.8" spread="11.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, Mean Pre Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.7" spread="7.37"/>
                    <measurement group_id="O2" value="71.9" spread="7.40"/>
                    <measurement group_id="O3" value="71.5" spread="7.59"/>
                    <measurement group_id="O4" value="71.6" spread="6.65"/>
                    <measurement group_id="O5" value="71.9" spread="6.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, 2 Hours, Pre Exercise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.1" spread="6.93"/>
                    <measurement group_id="O2" value="72.2" spread="6.09"/>
                    <measurement group_id="O3" value="71.3" spread="7.60"/>
                    <measurement group_id="O4" value="71.6" spread="7.76"/>
                    <measurement group_id="O5" value="72.2" spread="6.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, 9.5 Hours, Pre Exercise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.9" spread="6.05"/>
                    <measurement group_id="O2" value="70.5" spread="7.01"/>
                    <measurement group_id="O3" value="72.0" spread="7.65"/>
                    <measurement group_id="O4" value="71.2" spread="7.79"/>
                    <measurement group_id="O5" value="71.9" spread="7.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, 24 Hours, Pre Exercise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.1" spread="7.23"/>
                    <measurement group_id="O2" value="72.0" spread="7.84"/>
                    <measurement group_id="O3" value="72.2" spread="6.52"/>
                    <measurement group_id="O4" value="71.1" spread="8.25"/>
                    <measurement group_id="O5" value="72.9" spread="8.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assessment of Vital Signs: Heart Rate (HR)</title>
        <description>All participants rested for at least 10 minutes in the supine position prior to vital signs recordings. Vital signs Baseline values for HR for each treatment period were calculated using the mean value of triplicate pre dose readings. Triplicate readings were taken at least five minutes apart. Assessment was performed at pre dose, 2 hours, 9.5 hours and 24 hours prior to exercise challenge.</description>
        <time_frame>Pre dose, 2 hours, 9.5 hours and 24 hours prior to exercise challenge of each treatment period</time_frame>
        <population>All Subjects Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Eligible participants received Placebo matching GSK2190915 oral solution which was administered with 100 mL of water on Day 1 of each treatment period.</description>
          </group>
          <group group_id="O2">
            <title>GSK2190915 10 mg</title>
            <description>Eligible participants received single dose 10 mg GSK2190915 oral solution which was administered with 100 mL of water on Day 1 of each treatment period.</description>
          </group>
          <group group_id="O3">
            <title>GSK2190915 50 mg</title>
            <description>Eligible participants received single dose 50 mg GSK2190915 oral solution which was administered with 100 mL of water on Day 1 of each treatment period.</description>
          </group>
          <group group_id="O4">
            <title>GSK2190915 100 mg</title>
            <description>Eligible participants received single dose 100 mg GSK2190915 oral solution which was administered with 100 mL of water on Day 1 of each treatment period.</description>
          </group>
          <group group_id="O5">
            <title>GSK2190915 200 mg</title>
            <description>Eligible participants received single dose 200 mg GSK2190915 oral solution which was administered with 100 mL of water on Day 1 of each treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Vital Signs: Heart Rate (HR)</title>
          <description>All participants rested for at least 10 minutes in the supine position prior to vital signs recordings. Vital signs Baseline values for HR for each treatment period were calculated using the mean value of triplicate pre dose readings. Triplicate readings were taken at least five minutes apart. Assessment was performed at pre dose, 2 hours, 9.5 hours and 24 hours prior to exercise challenge.</description>
          <population>All Subjects Population.</population>
          <units>Beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="47"/>
                <count group_id="O4" value="45"/>
                <count group_id="O5" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mean Pre Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.0" spread="9.20"/>
                    <measurement group_id="O2" value="63.0" spread="7.62"/>
                    <measurement group_id="O3" value="64.0" spread="7.78"/>
                    <measurement group_id="O4" value="63.6" spread="7.48"/>
                    <measurement group_id="O5" value="64.7" spread="8.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 Hours, Pre Exercise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.5" spread="8.78"/>
                    <measurement group_id="O2" value="66.2" spread="9.08"/>
                    <measurement group_id="O3" value="67.2" spread="8.51"/>
                    <measurement group_id="O4" value="66.8" spread="6.95"/>
                    <measurement group_id="O5" value="67.2" spread="8.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9.5 Hours, Pre Exercise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.9" spread="11.35"/>
                    <measurement group_id="O2" value="69.4" spread="8.97"/>
                    <measurement group_id="O3" value="72.8" spread="9.16"/>
                    <measurement group_id="O4" value="72.3" spread="8.27"/>
                    <measurement group_id="O5" value="69.4" spread="9.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 Hours, Pre Excercise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.3" spread="10.90"/>
                    <measurement group_id="O2" value="65.7" spread="8.32"/>
                    <measurement group_id="O3" value="67.7" spread="8.75"/>
                    <measurement group_id="O4" value="65.9" spread="8.03"/>
                    <measurement group_id="O5" value="65.6" spread="9.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Abnormal Electrocardiogram (ECG) Findings</title>
        <description>All participants rested for at least 10 minutes in the supine position prior to ECG recordings. ECG Baseline values for each treatment period was calculated using the mean value of triplicate pre dose readings. Triplicate readings were taken at least five minutes apart. Assessment was performed at pre dose, 2 hours, 9.5 hours, 24 hours prior to exercise challenge and 60 minutes following exercise challenge at 2 hours. Participants with not clinically significant (NCS) abnormal values were reported. Potential clinical importance range for the ECG parameters are as follows: absolute QTc interval &gt;450 millisecond (msec), increase from Baseline QTc &gt;60 msec, PR interval &lt;110 and &gt;220 msec and QRS interval &lt;75 and &gt;110 msec. No participants reported clinically significant abnormal values.</description>
        <time_frame>Pre dose, 2 hours, 9.5 hours and 24 hours prior to exercise challenge and 60 minutes following exercise challenge at 2 hours of each treatment period</time_frame>
        <population>All Subjects Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Eligible participants received Placebo matching GSK2190915 oral solution which was administered with 100 mL of water on Day 1 of each treatment period.</description>
          </group>
          <group group_id="O2">
            <title>GSK2190915 10 mg</title>
            <description>Eligible participants received single dose 10 mg GSK2190915 oral solution which was administered with 100 mL of water on Day 1 of each treatment period.</description>
          </group>
          <group group_id="O3">
            <title>GSK2190915 50 mg</title>
            <description>Eligible participants received single dose 50 mg GSK2190915 oral solution which was administered with 100 mL of water on Day 1 of each treatment period.</description>
          </group>
          <group group_id="O4">
            <title>GSK2190915 100 mg</title>
            <description>Eligible participants received single dose 100 mg GSK2190915 oral solution which was administered with 100 mL of water on Day 1 of each treatment period.</description>
          </group>
          <group group_id="O5">
            <title>GSK2190915 200 mg</title>
            <description>Eligible participants received single dose 200 mg GSK2190915 oral solution which was administered with 100 mL of water on Day 1 of each treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Abnormal Electrocardiogram (ECG) Findings</title>
          <description>All participants rested for at least 10 minutes in the supine position prior to ECG recordings. ECG Baseline values for each treatment period was calculated using the mean value of triplicate pre dose readings. Triplicate readings were taken at least five minutes apart. Assessment was performed at pre dose, 2 hours, 9.5 hours, 24 hours prior to exercise challenge and 60 minutes following exercise challenge at 2 hours. Participants with not clinically significant (NCS) abnormal values were reported. Potential clinical importance range for the ECG parameters are as follows: absolute QTc interval &gt;450 millisecond (msec), increase from Baseline QTc &gt;60 msec, PR interval &lt;110 and &gt;220 msec and QRS interval &lt;75 and &gt;110 msec. No participants reported clinically significant abnormal values.</description>
          <population>All Subjects Population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="47"/>
                <count group_id="O4" value="45"/>
                <count group_id="O5" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre dose 1, Abnormal - NCS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="20"/>
                    <measurement group_id="O4" value="18"/>
                    <measurement group_id="O5" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre dose 2, Abnormal - NCS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="21"/>
                    <measurement group_id="O4" value="18"/>
                    <measurement group_id="O5" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre dose 3, Abnormal - NCS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="20"/>
                    <measurement group_id="O4" value="19"/>
                    <measurement group_id="O5" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 Hours, Pre Exercise, Abnormal  NCS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="19"/>
                    <measurement group_id="O5" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 Hours, 60 minutes, Abnormal  NCS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="17"/>
                    <measurement group_id="O4" value="19"/>
                    <measurement group_id="O5" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9.5 Hours, Pre exercise, Abnormal  NCS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="17"/>
                    <measurement group_id="O4" value="16"/>
                    <measurement group_id="O5" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 Hours, Pre exercise, Abnormal  NCS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="19"/>
                    <measurement group_id="O4" value="18"/>
                    <measurement group_id="O5" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assessment of Clinical Chemistry Parameters: Albumin, Total Protein</title>
        <description>Blood samples were collected for the assessment of clinical chemistry parameters for albumin and total protein at pre dose and 25 hours and 30 minutes. Participants had to fast for at least 8 hours prior to visit. During treatment periods, fasting continued until a light meal was allowed 1 hour post dose.</description>
        <time_frame>Pre dose and 25 hours and 30 minutes post dose of each treatment period</time_frame>
        <population>All Subjects Population. Only those participants with data available at the indicated time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Eligible participants received Placebo matching GSK2190915 oral solution which was administered with 100 mL of water on Day 1 of each treatment period.</description>
          </group>
          <group group_id="O2">
            <title>GSK2190915 10 mg</title>
            <description>Eligible participants received single dose 10 mg GSK2190915 oral solution which was administered with 100 mL of water on Day 1 of each treatment period.</description>
          </group>
          <group group_id="O3">
            <title>GSK2190915 50 mg</title>
            <description>Eligible participants received single dose 50 mg GSK2190915 oral solution which was administered with 100 mL of water on Day 1 of each treatment period.</description>
          </group>
          <group group_id="O4">
            <title>GSK2190915 100 mg</title>
            <description>Eligible participants received single dose 100 mg GSK2190915 oral solution which was administered with 100 mL of water on Day 1 of each treatment period.</description>
          </group>
          <group group_id="O5">
            <title>GSK2190915 200 mg</title>
            <description>Eligible participants received single dose 200 mg GSK2190915 oral solution which was administered with 100 mL of water on Day 1 of each treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Clinical Chemistry Parameters: Albumin, Total Protein</title>
          <description>Blood samples were collected for the assessment of clinical chemistry parameters for albumin and total protein at pre dose and 25 hours and 30 minutes. Participants had to fast for at least 8 hours prior to visit. During treatment periods, fasting continued until a light meal was allowed 1 hour post dose.</description>
          <population>All Subjects Population. Only those participants with data available at the indicated time points were analyzed.</population>
          <units>Gram/liter (G/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="47"/>
                <count group_id="O4" value="45"/>
                <count group_id="O5" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Albumin, Pre dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="44"/>
                    <count group_id="O2" value="44"/>
                    <count group_id="O3" value="47"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.5000" spread="3.30961"/>
                    <measurement group_id="O2" value="44.9091" spread="2.60427"/>
                    <measurement group_id="O3" value="44.4894" spread="3.24956"/>
                    <measurement group_id="O4" value="44.8667" spread="2.54594"/>
                    <measurement group_id="O5" value="44.9778" spread="3.20148"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin, 25Hours 30minutes</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="45"/>
                    <count group_id="O3" value="47"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.8140" spread="2.23879"/>
                    <measurement group_id="O2" value="45.4222" spread="3.08581"/>
                    <measurement group_id="O3" value="45.7021" spread="2.43091"/>
                    <measurement group_id="O4" value="45.9111" spread="2.16188"/>
                    <measurement group_id="O5" value="45.8444" spread="2.53122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total protein, Pre dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="44"/>
                    <count group_id="O2" value="44"/>
                    <count group_id="O3" value="47"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.9" spread="5.32"/>
                    <measurement group_id="O2" value="72.5" spread="4.05"/>
                    <measurement group_id="O3" value="71.4" spread="5.11"/>
                    <measurement group_id="O4" value="71.6" spread="4.16"/>
                    <measurement group_id="O5" value="71.3" spread="4.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total protein, 25Hours 30minutes</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="45"/>
                    <count group_id="O3" value="47"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.2" spread="4.00"/>
                    <measurement group_id="O2" value="72.9" spread="3.59"/>
                    <measurement group_id="O3" value="73.5" spread="3.97"/>
                    <measurement group_id="O4" value="72.6" spread="2.73"/>
                    <measurement group_id="O5" value="72.8" spread="3.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assessment of Clinical Chemistry Parameters: Alkaline Phosphatase (ALP), Alanine Amino Transferase (ALT), Aspartate Amino Transferase (AST), Gamma Glutamyl Transferase (GGT)</title>
        <description>Blood samples were collected for the assessment of clinical chemistry parameters for ALP, ALT, AST and GGT at pre dose and 25 hours and 30 minutes. Participants had to fast for at least 8 hours prior to visit. During treatment periods, fasting continued until a light meal was allowed 1 hour post dose.</description>
        <time_frame>Pre dose and 25 hours and 30 minutes post dose of each treatment period</time_frame>
        <population>All Subjects Population. Only those participants available at the indicated time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Eligible participants received Placebo matching GSK2190915 oral solution which was administered with 100 mL of water on Day 1 of each treatment period.</description>
          </group>
          <group group_id="O2">
            <title>GSK2190915 10 mg</title>
            <description>Eligible participants received single dose 10 mg GSK2190915 oral solution which was administered with 100 mL of water on Day 1 of each treatment period.</description>
          </group>
          <group group_id="O3">
            <title>GSK2190915 50 mg</title>
            <description>Eligible participants received single dose 50 mg GSK2190915 oral solution which was administered with 100 mL of water on Day 1 of each treatment period.</description>
          </group>
          <group group_id="O4">
            <title>GSK2190915 100 mg</title>
            <description>Eligible participants received single dose 100 mg GSK2190915 oral solution which was administered with 100 mL of water on Day 1 of each treatment period.</description>
          </group>
          <group group_id="O5">
            <title>GSK2190915 200 mg</title>
            <description>Eligible participants received single dose 200 mg GSK2190915 oral solution which was administered with 100 mL of water on Day 1 of each treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Clinical Chemistry Parameters: Alkaline Phosphatase (ALP), Alanine Amino Transferase (ALT), Aspartate Amino Transferase (AST), Gamma Glutamyl Transferase (GGT)</title>
          <description>Blood samples were collected for the assessment of clinical chemistry parameters for ALP, ALT, AST and GGT at pre dose and 25 hours and 30 minutes. Participants had to fast for at least 8 hours prior to visit. During treatment periods, fasting continued until a light meal was allowed 1 hour post dose.</description>
          <population>All Subjects Population. Only those participants available at the indicated time points were analyzed.</population>
          <units>International units per liter (IU/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="47"/>
                <count group_id="O4" value="45"/>
                <count group_id="O5" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ALP, Pre dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="44"/>
                    <count group_id="O2" value="44"/>
                    <count group_id="O3" value="47"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.6" spread="26.15"/>
                    <measurement group_id="O2" value="75.5" spread="24.29"/>
                    <measurement group_id="O3" value="75.6" spread="25.64"/>
                    <measurement group_id="O4" value="74.6" spread="23.85"/>
                    <measurement group_id="O5" value="75.3" spread="22.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALP, 25 Hours 30 minutes</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="45"/>
                    <count group_id="O3" value="47"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.3" spread="23.26"/>
                    <measurement group_id="O2" value="75.7" spread="23.75"/>
                    <measurement group_id="O3" value="76.9" spread="27.15"/>
                    <measurement group_id="O4" value="75.2" spread="23.71"/>
                    <measurement group_id="O5" value="75.8" spread="25.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT, Pre dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="44"/>
                    <count group_id="O2" value="44"/>
                    <count group_id="O3" value="47"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.7" spread="19.09"/>
                    <measurement group_id="O2" value="30.1" spread="17.66"/>
                    <measurement group_id="O3" value="31.2" spread="18.97"/>
                    <measurement group_id="O4" value="32.2" spread="26.62"/>
                    <measurement group_id="O5" value="39.6" spread="71.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT, 25 Hours 30 minutes</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="45"/>
                    <count group_id="O3" value="47"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.7" spread="20.04"/>
                    <measurement group_id="O2" value="29.6" spread="16.08"/>
                    <measurement group_id="O3" value="32.4" spread="19.49"/>
                    <measurement group_id="O4" value="31.4" spread="23.34"/>
                    <measurement group_id="O5" value="38.5" spread="66.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST, Pre dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="44"/>
                    <count group_id="O2" value="44"/>
                    <count group_id="O3" value="47"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.5" spread="13.29"/>
                    <measurement group_id="O2" value="24.0" spread="10.26"/>
                    <measurement group_id="O3" value="25.4" spread="14.81"/>
                    <measurement group_id="O4" value="24.6" spread="11.42"/>
                    <measurement group_id="O5" value="27.3" spread="31.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST, 25 Hours 30 minutes</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="45"/>
                    <count group_id="O3" value="47"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.0" spread="10.14"/>
                    <measurement group_id="O2" value="23.3" spread="8.82"/>
                    <measurement group_id="O3" value="27.3" spread="19.39"/>
                    <measurement group_id="O4" value="23.9" spread="9.72"/>
                    <measurement group_id="O5" value="26.9" spread="31.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GGT, Pre dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="41"/>
                    <count group_id="O3" value="46"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.8" spread="29.45"/>
                    <measurement group_id="O2" value="28.1" spread="21.98"/>
                    <measurement group_id="O3" value="31.5" spread="27.08"/>
                    <measurement group_id="O4" value="32.8" spread="39.54"/>
                    <measurement group_id="O5" value="30.3" spread="30.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GGT, 2 5Hours 30 minutes</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="46"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.5" spread="25.87"/>
                    <measurement group_id="O2" value="27.7" spread="20.81"/>
                    <measurement group_id="O3" value="32.9" spread="29.08"/>
                    <measurement group_id="O4" value="32.8" spread="38.13"/>
                    <measurement group_id="O5" value="31.0" spread="31.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assessment of Clinical Chemistry Parameters: Direct Bilirubin, Total Bilirubin, Creatinine</title>
        <description>Blood samples were collected for the assessment of clinical chemistry parameters for direct bilirubin, total bilirubin and creatinine at pre dose and 25 hours and 30 minutes. Participants had to fast for at least 8 hours prior to visit. During treatment periods, fasting continued until a light meal was allowed 1 hour post dose.</description>
        <time_frame>Pre dose and 25 hours and 30 minutes post dose of each treatment period</time_frame>
        <population>All Subjects Population. Only those participants available at the indicated time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Eligible participants received Placebo matching GSK2190915 oral solution which was administered with 100 mL of water on Day 1 of each treatment period.</description>
          </group>
          <group group_id="O2">
            <title>GSK2190915 10 mg</title>
            <description>Eligible participants received single dose 10 mg GSK2190915 oral solution which was administered with 100 mL of water on Day 1 of each treatment period.</description>
          </group>
          <group group_id="O3">
            <title>GSK2190915 50 mg</title>
            <description>Eligible participants received single dose 50 mg GSK2190915 oral solution which was administered with 100 mL of water on Day 1 of each treatment period.</description>
          </group>
          <group group_id="O4">
            <title>GSK2190915 100 mg</title>
            <description>Eligible participants received single dose 100 mg GSK2190915 oral solution which was administered with 100 mL of water on Day 1 of each treatment period.</description>
          </group>
          <group group_id="O5">
            <title>GSK2190915 200 mg</title>
            <description>Eligible participants received single dose 200 mg GSK2190915 oral solution which was administered with 100 mL of water on Day 1 of each treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Clinical Chemistry Parameters: Direct Bilirubin, Total Bilirubin, Creatinine</title>
          <description>Blood samples were collected for the assessment of clinical chemistry parameters for direct bilirubin, total bilirubin and creatinine at pre dose and 25 hours and 30 minutes. Participants had to fast for at least 8 hours prior to visit. During treatment periods, fasting continued until a light meal was allowed 1 hour post dose.</description>
          <population>All Subjects Population. Only those participants available at the indicated time points were analyzed.</population>
          <units>Micromoles per liter (mol/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="47"/>
                <count group_id="O4" value="45"/>
                <count group_id="O5" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Direct Bilirubin, Pre dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="44"/>
                    <count group_id="O3" value="46"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.361" spread="1.8484"/>
                    <measurement group_id="O2" value="2.332" spread="1.4326"/>
                    <measurement group_id="O3" value="2.230" spread="1.8336"/>
                    <measurement group_id="O4" value="2.318" spread="1.6769"/>
                    <measurement group_id="O5" value="2.280" spread="2.1874"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Direct Bilirubin, 25 Hours 30 minute</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="45"/>
                    <count group_id="O3" value="46"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.443" spread="1.8938"/>
                    <measurement group_id="O2" value="2.204" spread="1.2952"/>
                    <measurement group_id="O3" value="2.453" spread="2.3266"/>
                    <measurement group_id="O4" value="2.584" spread="1.8454"/>
                    <measurement group_id="O5" value="2.242" spread="1.9230"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Bilirubin, Pre dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="44"/>
                    <count group_id="O2" value="44"/>
                    <count group_id="O3" value="47"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.804" spread="5.6386"/>
                    <measurement group_id="O2" value="11.348" spread="5.0173"/>
                    <measurement group_id="O3" value="11.060" spread="5.6473"/>
                    <measurement group_id="O4" value="11.438" spread="5.8652"/>
                    <measurement group_id="O5" value="11.134" spread="7.3966"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Bilirubin, 25 Hours 30 minutes</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="45"/>
                    <count group_id="O3" value="47"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.737" spread="5.3078"/>
                    <measurement group_id="O2" value="10.412" spread="4.8479"/>
                    <measurement group_id="O3" value="11.388" spread="6.1270"/>
                    <measurement group_id="O4" value="10.982" spread="5.8387"/>
                    <measurement group_id="O5" value="10.906" spread="6.4426"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine, Pre dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="44"/>
                    <count group_id="O2" value="44"/>
                    <count group_id="O3" value="47"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.96594" spread="18.34701"/>
                    <measurement group_id="O2" value="87.93791" spread="20.15153"/>
                    <measurement group_id="O3" value="86.23702" spread="13.21355"/>
                    <measurement group_id="O4" value="86.80880" spread="13.90414"/>
                    <measurement group_id="O5" value="85.96409" spread="14.50499"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine, 25 Hours 30 minutes</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="45"/>
                    <count group_id="O3" value="47"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.83023" spread="14.40704"/>
                    <measurement group_id="O2" value="86.71058" spread="14.11612"/>
                    <measurement group_id="O3" value="87.91098" spread="13.81935"/>
                    <measurement group_id="O4" value="87.57493" spread="13.41632"/>
                    <measurement group_id="O5" value="87.57493" spread="14.84895"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assessment of Clinical Chemistry Parameters: Calcium, Chloride, Glucose, Potassium, Sodium, Urea/Blood Urea Nitrogen (BUN)</title>
        <description>Blood samples were collected for the assessment of clinical chemistry parameters for calcium, chloride, glucose, potassium, sodium and urea/BUN at pre dose and 25 hours and 30 minutes post dose. Participants had to fast for at least 8 hours prior to visit. Participants fasted for glucose blood sample. During treatment periods, fasting continued until a light meal was allowed 1 hour post dose.</description>
        <time_frame>Pre dose and 25 hours and 30 minutes post dose of each treatment period</time_frame>
        <population>All Subjects Population. Only those participants with data available at the indicated time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Eligible participants received Placebo matching GSK2190915 oral solution which was administered with 100 mL of water on Day 1 of each treatment period.</description>
          </group>
          <group group_id="O2">
            <title>GSK2190915 10 mg</title>
            <description>Eligible participants received single dose 10 mg GSK2190915 oral solution which was administered with 100 mL of water on Day 1 of each treatment period.</description>
          </group>
          <group group_id="O3">
            <title>GSK2190915 50 mg</title>
            <description>Eligible participants received single dose 50 mg GSK2190915 oral solution which was administered with 100 mL of water on Day 1 of each treatment period.</description>
          </group>
          <group group_id="O4">
            <title>GSK2190915 100 mg</title>
            <description>Eligible participants received single dose 100 mg GSK2190915 oral solution which was administered with 100 mL of water on Day 1 of each treatment period.</description>
          </group>
          <group group_id="O5">
            <title>GSK2190915 200 mg</title>
            <description>Eligible participants received single dose 200 mg GSK2190915 oral solution which was administered with 100 mL of water on Day 1 of each treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Clinical Chemistry Parameters: Calcium, Chloride, Glucose, Potassium, Sodium, Urea/Blood Urea Nitrogen (BUN)</title>
          <description>Blood samples were collected for the assessment of clinical chemistry parameters for calcium, chloride, glucose, potassium, sodium and urea/BUN at pre dose and 25 hours and 30 minutes post dose. Participants had to fast for at least 8 hours prior to visit. Participants fasted for glucose blood sample. During treatment periods, fasting continued until a light meal was allowed 1 hour post dose.</description>
          <population>All Subjects Population. Only those participants with data available at the indicated time points were analyzed.</population>
          <units>Millimole per liter (mmol/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="47"/>
                <count group_id="O4" value="45"/>
                <count group_id="O5" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Calcium, Pre dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="44"/>
                    <count group_id="O2" value="44"/>
                    <count group_id="O3" value="47"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.35494" spread="0.112125"/>
                    <measurement group_id="O2" value="2.36061" spread="0.107377"/>
                    <measurement group_id="O3" value="2.35910" spread="0.112041"/>
                    <measurement group_id="O4" value="2.35417" spread="0.109681"/>
                    <measurement group_id="O5" value="2.35084" spread="0.108088"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium, 25 Hours 30 minutes</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="45"/>
                    <count group_id="O3" value="47"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.37605" spread="0.105831"/>
                    <measurement group_id="O2" value="2.38300" spread="0.110640"/>
                    <measurement group_id="O3" value="2.39308" spread="0.096186"/>
                    <measurement group_id="O4" value="2.38078" spread="0.091593"/>
                    <measurement group_id="O5" value="2.37136" spread="0.093348"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chloride, Pre dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="44"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="47"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105.2" spread="1.92"/>
                    <measurement group_id="O2" value="105.1" spread="2.04"/>
                    <measurement group_id="O3" value="105.2" spread="2.07"/>
                    <measurement group_id="O4" value="105.0" spread="2.34"/>
                    <measurement group_id="O5" value="105.1" spread="2.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chloride, 25 Hours 30 minutes</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="45"/>
                    <count group_id="O3" value="47"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104.7" spread="2.36"/>
                    <measurement group_id="O2" value="105.4" spread="1.85"/>
                    <measurement group_id="O3" value="105.2" spread="2.28"/>
                    <measurement group_id="O4" value="104.8" spread="2.05"/>
                    <measurement group_id="O5" value="105.5" spread="2.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose, Pre dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="44"/>
                    <count group_id="O2" value="44"/>
                    <count group_id="O3" value="47"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.80162" spread="0.783522"/>
                    <measurement group_id="O2" value="4.73601" spread="0.804663"/>
                    <measurement group_id="O3" value="4.97937" spread="0.843434"/>
                    <measurement group_id="O4" value="4.88735" spread="0.770075"/>
                    <measurement group_id="O5" value="4.95273" spread="0.768704"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose, 25 Hours 30 minutes</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="45"/>
                    <count group_id="O3" value="47"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.99203" spread="0.859137"/>
                    <measurement group_id="O2" value="4.96753" spread="0.892300"/>
                    <measurement group_id="O3" value="4.73370" spread="0.824460"/>
                    <measurement group_id="O4" value="5.02921" spread="1.004730"/>
                    <measurement group_id="O5" value="5.07855" spread="1.164605"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium, Pre dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="44"/>
                    <count group_id="O2" value="44"/>
                    <count group_id="O3" value="47"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.40" spread="0.328"/>
                    <measurement group_id="O2" value="4.40" spread="0.456"/>
                    <measurement group_id="O3" value="4.31" spread="0.386"/>
                    <measurement group_id="O4" value="4.29" spread="0.320"/>
                    <measurement group_id="O5" value="4.36" spread="0.422"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium, 25 Hours 30 minutes</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="45"/>
                    <count group_id="O3" value="47"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.43" spread="0.342"/>
                    <measurement group_id="O2" value="4.51" spread="0.362"/>
                    <measurement group_id="O3" value="4.44" spread="0.374"/>
                    <measurement group_id="O4" value="4.44" spread="0.322"/>
                    <measurement group_id="O5" value="4.50" spread="0.333"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium, Pre dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="44"/>
                    <count group_id="O2" value="44"/>
                    <count group_id="O3" value="47"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="140.6" spread="2.16"/>
                    <measurement group_id="O2" value="140.9" spread="2.23"/>
                    <measurement group_id="O3" value="140.1" spread="2.17"/>
                    <measurement group_id="O4" value="139.9" spread="2.37"/>
                    <measurement group_id="O5" value="140.2" spread="1.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium, 25 Hours 30 minutes</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="45"/>
                    <count group_id="O3" value="47"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="140.0" spread="2.13"/>
                    <measurement group_id="O2" value="140.6" spread="2.34"/>
                    <measurement group_id="O3" value="140.3" spread="2.18"/>
                    <measurement group_id="O4" value="139.6" spread="2.03"/>
                    <measurement group_id="O5" value="140.2" spread="2.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urea/BUN, Pre dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="44"/>
                    <count group_id="O2" value="44"/>
                    <count group_id="O3" value="47"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.8175" spread="1.32593"/>
                    <measurement group_id="O2" value="5.6390" spread="1.56766"/>
                    <measurement group_id="O3" value="5.7652" spread="1.24779"/>
                    <measurement group_id="O4" value="5.7120" spread="1.25759"/>
                    <measurement group_id="O5" value="5.6565" spread="1.31601"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urea/BUN, 25 Hours 30 minutes</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="45"/>
                    <count group_id="O3" value="47"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6539" spread="1.12605"/>
                    <measurement group_id="O2" value="5.5930" spread="1.11343"/>
                    <measurement group_id="O3" value="5.7424" spread="1.06537"/>
                    <measurement group_id="O4" value="5.8786" spread="1.09666"/>
                    <measurement group_id="O5" value="5.5771" spread="1.30126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assessment of Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Total Neutrophils (TN) (ANC - Absolute Neutrophil Count), Platelet Count, White Blood Cell Count (WBC)</title>
        <description>Blood samples were collected for the assessment of hematology parameters for basophils, eosinophils, lymphocytes, monocytes, TN, platelet count, WBC at pre dose and 25 hours and 30 minutes post dose. Participants had to fast for at least 8 hours prior to visit. During treatment periods, fasting continued until a light meal was allowed 1 hour post dose.</description>
        <time_frame>Pre dose and 25 hours and 30 minutes post dose of each treatment period</time_frame>
        <population>All Subjects Population. Only those participants with data available at the indicated time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Eligible participants received Placebo matching GSK2190915 oral solution which was administered with 100 mL of water on Day 1 of each treatment period.</description>
          </group>
          <group group_id="O2">
            <title>GSK2190915 10 mg</title>
            <description>Eligible participants received single dose 10 mg GSK2190915 oral solution which was administered with 100 mL of water on Day 1 of each treatment period.</description>
          </group>
          <group group_id="O3">
            <title>GSK2190915 50 mg</title>
            <description>Eligible participants received single dose 50 mg GSK2190915 oral solution which was administered with 100 mL of water on Day 1 of each treatment period.</description>
          </group>
          <group group_id="O4">
            <title>GSK2190915 100 mg</title>
            <description>Eligible participants received single dose 100 mg GSK2190915 oral solution which was administered with 100 mL of water on Day 1 of each treatment period.</description>
          </group>
          <group group_id="O5">
            <title>GSK2190915 200 mg</title>
            <description>Eligible participants received single dose 200 mg GSK2190915 oral solution which was administered with 100 mL of water on Day 1 of each treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Total Neutrophils (TN) (ANC - Absolute Neutrophil Count), Platelet Count, White Blood Cell Count (WBC)</title>
          <description>Blood samples were collected for the assessment of hematology parameters for basophils, eosinophils, lymphocytes, monocytes, TN, platelet count, WBC at pre dose and 25 hours and 30 minutes post dose. Participants had to fast for at least 8 hours prior to visit. During treatment periods, fasting continued until a light meal was allowed 1 hour post dose.</description>
          <population>All Subjects Population. Only those participants with data available at the indicated time points were analyzed.</population>
          <units>Cells x 10^9 per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="47"/>
                <count group_id="O4" value="45"/>
                <count group_id="O5" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Basophils, Pre dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="18"/>
                    <count group_id="O5" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0306" spread="0.01326"/>
                    <measurement group_id="O2" value="0.0281" spread="0.01065"/>
                    <measurement group_id="O3" value="0.0276" spread="0.01133"/>
                    <measurement group_id="O4" value="0.0316" spread="0.02112"/>
                    <measurement group_id="O5" value="0.0298" spread="0.01261"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Basophils, 25 Hours 30 minutes</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="18"/>
                    <count group_id="O5" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0242" spread="0.01064"/>
                    <measurement group_id="O2" value="0.0303" spread="0.00968"/>
                    <measurement group_id="O3" value="0.0333" spread="0.01805"/>
                    <measurement group_id="O4" value="0.0282" spread="0.00944"/>
                    <measurement group_id="O5" value="0.0252" spread="0.01171"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils, Pre dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="18"/>
                    <count group_id="O5" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2638" spread="0.21459"/>
                    <measurement group_id="O2" value="0.2574" spread="0.20600"/>
                    <measurement group_id="O3" value="0.2392" spread="0.15458"/>
                    <measurement group_id="O4" value="0.2563" spread="0.21963"/>
                    <measurement group_id="O5" value="0.2166" spread="0.11200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils, 25 Hours 30 minutes</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="18"/>
                    <count group_id="O5" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2241" spread="0.15104"/>
                    <measurement group_id="O2" value="0.2610" spread="0.18803"/>
                    <measurement group_id="O3" value="0.2431" spread="0.15657"/>
                    <measurement group_id="O4" value="0.2271" spread="0.18567"/>
                    <measurement group_id="O5" value="0.1974" spread="0.10502"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocyte, Pre dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="28"/>
                    <count group_id="O2" value="28"/>
                    <count group_id="O3" value="27"/>
                    <count group_id="O4" value="28"/>
                    <count group_id="O5" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2320" spread="0.62143"/>
                    <measurement group_id="O2" value="2.2139" spread="0.56983"/>
                    <measurement group_id="O3" value="2.3156" spread="0.56904"/>
                    <measurement group_id="O4" value="2.3581" spread="0.66985"/>
                    <measurement group_id="O5" value="2.1852" spread="0.69204"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocyte, 25 Hours 30 minutes</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                    <count group_id="O2" value="28"/>
                    <count group_id="O3" value="29"/>
                    <count group_id="O4" value="28"/>
                    <count group_id="O5" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8281" spread="0.47068"/>
                    <measurement group_id="O2" value="1.8847" spread="0.55807"/>
                    <measurement group_id="O3" value="1.9052" spread="0.48399"/>
                    <measurement group_id="O4" value="1.8809" spread="0.49456"/>
                    <measurement group_id="O5" value="1.8677" spread="0.62646"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocyte, Pre dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="18"/>
                    <count group_id="O5" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4673" spread="0.18438"/>
                    <measurement group_id="O2" value="0.4366" spread="0.11641"/>
                    <measurement group_id="O3" value="0.4799" spread="0.10725"/>
                    <measurement group_id="O4" value="0.4671" spread="0.11368"/>
                    <measurement group_id="O5" value="0.4307" spread="0.12690"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocyte, 25 Hours 30 minutes</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="18"/>
                    <count group_id="O5" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3912" spread="0.09575"/>
                    <measurement group_id="O2" value="0.4289" spread="0.12575"/>
                    <measurement group_id="O3" value="0.4489" spread="0.13018"/>
                    <measurement group_id="O4" value="0.4190" spread="0.11797"/>
                    <measurement group_id="O5" value="0.4084" spread="0.15112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TN, Pre dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="28"/>
                    <count group_id="O2" value="28"/>
                    <count group_id="O3" value="27"/>
                    <count group_id="O4" value="28"/>
                    <count group_id="O5" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4340" spread="0.98614"/>
                    <measurement group_id="O2" value="3.3645" spread="0.92934"/>
                    <measurement group_id="O3" value="3.4151" spread="0.96375"/>
                    <measurement group_id="O4" value="3.6047" spread="1.19442"/>
                    <measurement group_id="O5" value="3.5448" spread="1.05765"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TN, 25 Hours 30 minutes</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                    <count group_id="O2" value="28"/>
                    <count group_id="O3" value="29"/>
                    <count group_id="O4" value="28"/>
                    <count group_id="O5" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6062" spread="1.16759"/>
                    <measurement group_id="O2" value="3.6962" spread="0.92202"/>
                    <measurement group_id="O3" value="3.7720" spread="1.08800"/>
                    <measurement group_id="O4" value="3.7813" spread="1.26257"/>
                    <measurement group_id="O5" value="3.5289" spread="1.13473"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Plateletcount, Pre dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="44"/>
                    <count group_id="O2" value="44"/>
                    <count group_id="O3" value="47"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="241.8" spread="58.19"/>
                    <measurement group_id="O2" value="238.0" spread="51.85"/>
                    <measurement group_id="O3" value="243.0" spread="47.46"/>
                    <measurement group_id="O4" value="240.1" spread="50.26"/>
                    <measurement group_id="O5" value="238.4" spread="49.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Plateletcount, 25 Hours 30 minutes</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="45"/>
                    <count group_id="O3" value="46"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="242.7" spread="55.97"/>
                    <measurement group_id="O2" value="239.0" spread="48.39"/>
                    <measurement group_id="O3" value="243.3" spread="46.73"/>
                    <measurement group_id="O4" value="240.5" spread="50.51"/>
                    <measurement group_id="O5" value="238.0" spread="52.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC count, Pre dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="44"/>
                    <count group_id="O2" value="44"/>
                    <count group_id="O3" value="47"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.69" spread="1.689"/>
                    <measurement group_id="O2" value="6.58" spread="1.638"/>
                    <measurement group_id="O3" value="6.77" spread="1.627"/>
                    <measurement group_id="O4" value="6.79" spread="1.726"/>
                    <measurement group_id="O5" value="6.50" spread="1.465"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC count, 25 Hours 30 minutes</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="45"/>
                    <count group_id="O3" value="46"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.56" spread="1.708"/>
                    <measurement group_id="O2" value="6.56" spread="1.434"/>
                    <measurement group_id="O3" value="6.67" spread="1.605"/>
                    <measurement group_id="O4" value="6.75" spread="1.650"/>
                    <measurement group_id="O5" value="6.39" spread="1.681"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assessment of Hematology Parameters: Hemoglobin, Mean Corpuscle Hemoglobin Concentration (MCHC)</title>
        <description>Blood samples were collected for the assessment of hematology parameters for hemoglobin and MCHC at pre dose and 25 hours and 30 minutes post dose. Participants had to fast for at least 8 hours prior to visit. During treatment periods, fasting continued until a light meal was allowed 1 hour post dose.</description>
        <time_frame>Pre dose and 25 hours and 30 minutes post dose of each treatment period</time_frame>
        <population>All Subjects Population. Only those participants with data available at the indicated time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Eligible participants received Placebo matching GSK2190915 oral solution which was administered with 100 mL of water on Day 1 of each treatment period.</description>
          </group>
          <group group_id="O2">
            <title>GSK2190915 10 mg</title>
            <description>Eligible participants received single dose 10 mg GSK2190915 oral solution which was administered with 100 mL of water on Day 1 of each treatment period.</description>
          </group>
          <group group_id="O3">
            <title>GSK2190915 50 mg</title>
            <description>Eligible participants received single dose 50 mg GSK2190915 oral solution which was administered with 100 mL of water on Day 1 of each treatment period.</description>
          </group>
          <group group_id="O4">
            <title>GSK2190915 100 mg</title>
            <description>Eligible participants received single dose 100 mg GSK2190915 oral solution which was administered with 100 mL of water on Day 1 of each treatment period.</description>
          </group>
          <group group_id="O5">
            <title>GSK2190915 200 mg</title>
            <description>Eligible participants received single dose 200 mg GSK2190915 oral solution which was administered with 100 mL of water on Day 1 of each treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Hematology Parameters: Hemoglobin, Mean Corpuscle Hemoglobin Concentration (MCHC)</title>
          <description>Blood samples were collected for the assessment of hematology parameters for hemoglobin and MCHC at pre dose and 25 hours and 30 minutes post dose. Participants had to fast for at least 8 hours prior to visit. During treatment periods, fasting continued until a light meal was allowed 1 hour post dose.</description>
          <population>All Subjects Population. Only those participants with data available at the indicated time points were analyzed.</population>
          <units>G/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="47"/>
                <count group_id="O4" value="45"/>
                <count group_id="O5" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hemoglobin, Pre dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="44"/>
                    <count group_id="O2" value="44"/>
                    <count group_id="O3" value="47"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="152.0" spread="13.75"/>
                    <measurement group_id="O2" value="152.9" spread="13.00"/>
                    <measurement group_id="O3" value="151.3" spread="14.44"/>
                    <measurement group_id="O4" value="152.4" spread="12.95"/>
                    <measurement group_id="O5" value="151.3" spread="14.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin, 25 hours 30 minutes</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="45"/>
                    <count group_id="O3" value="46"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="151.1" spread="12.84"/>
                    <measurement group_id="O2" value="151.9" spread="13.80"/>
                    <measurement group_id="O3" value="157.8" spread="45.11"/>
                    <measurement group_id="O4" value="151.3" spread="12.93"/>
                    <measurement group_id="O5" value="151.2" spread="13.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MCHC, Pre dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="44"/>
                    <count group_id="O2" value="44"/>
                    <count group_id="O3" value="47"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="340.5" spread="8.55"/>
                    <measurement group_id="O2" value="339.3" spread="8.77"/>
                    <measurement group_id="O3" value="341.2" spread="8.35"/>
                    <measurement group_id="O4" value="340.0" spread="8.88"/>
                    <measurement group_id="O5" value="338.6" spread="9.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MCHC, 25 hours 30 minutes</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="45"/>
                    <count group_id="O3" value="46"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="340.2" spread="9.14"/>
                    <measurement group_id="O2" value="341.1" spread="7.43"/>
                    <measurement group_id="O3" value="340.4" spread="9.30"/>
                    <measurement group_id="O4" value="340.4" spread="9.05"/>
                    <measurement group_id="O5" value="339.8" spread="9.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assessment of Hematology Parameters: Hematocrit</title>
        <description>Blood samples were collected for the assessment of hematology parameters for hematocrit at pre dose and 25 hours and 30 minutes post dose. Participants had to fast for at least 8 hours prior to visit. During treatment periods, fasting continued until a light meal was allowed 1 hour post dose.</description>
        <time_frame>Pre dose and 25 hours and 30 minutes post dose of each treatment period</time_frame>
        <population>All Subjects Population. Only those participants with data available at the indicated time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Eligible participants received Placebo matching GSK2190915 oral solution which was administered with 100 mL of water on Day 1 of each treatment period.</description>
          </group>
          <group group_id="O2">
            <title>GSK2190915 10 mg</title>
            <description>Eligible participants received single dose 10 mg GSK2190915 oral solution which was administered with 100 mL of water on Day 1 of each treatment period.</description>
          </group>
          <group group_id="O3">
            <title>GSK2190915 50 mg</title>
            <description>Eligible participants received single dose 50 mg GSK2190915 oral solution which was administered with 100 mL of water on Day 1 of each treatment period.</description>
          </group>
          <group group_id="O4">
            <title>GSK2190915 100 mg</title>
            <description>Eligible participants received single dose 100 mg GSK2190915 oral solution which was administered with 100 mL of water on Day 1 of each treatment period.</description>
          </group>
          <group group_id="O5">
            <title>GSK2190915 200 mg</title>
            <description>Eligible participants received single dose 200 mg GSK2190915 oral solution which was administered with 100 mL of water on Day 1 of each treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Hematology Parameters: Hematocrit</title>
          <description>Blood samples were collected for the assessment of hematology parameters for hematocrit at pre dose and 25 hours and 30 minutes post dose. Participants had to fast for at least 8 hours prior to visit. During treatment periods, fasting continued until a light meal was allowed 1 hour post dose.</description>
          <population>All Subjects Population. Only those participants with data available at the indicated time points were analyzed.</population>
          <units>Ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="47"/>
                <count group_id="O4" value="45"/>
                <count group_id="O5" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="44"/>
                    <count group_id="O2" value="44"/>
                    <count group_id="O3" value="47"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4463" spread="0.03720"/>
                    <measurement group_id="O2" value="0.4503" spread="0.03423"/>
                    <measurement group_id="O3" value="0.4431" spread="0.03885"/>
                    <measurement group_id="O4" value="0.4480" spread="0.03265"/>
                    <measurement group_id="O5" value="0.4465" spread="0.03864"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>25 Hours 30 Minutes</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="45"/>
                    <count group_id="O3" value="46"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4440" spread="0.03186"/>
                    <measurement group_id="O2" value="0.4451" spread="0.03765"/>
                    <measurement group_id="O3" value="0.4453" spread="0.03375"/>
                    <measurement group_id="O4" value="0.4442" spread="0.03244"/>
                    <measurement group_id="O5" value="0.4448" spread="0.03628"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assessment of Hematology Parameters: Mean Corpuscle Hemoglobin (MCH)</title>
        <description>Blood samples were collected for the assessment of hematology parameter for MCH at pre dose and 25 hours and 30 minutes post dose. Participants had to fast for at least 8 hours prior to visit. During treatment periods, fasting continued until a light meal was allowed 1 hour post dose.</description>
        <time_frame>Pre dose and 25 hours and 30 minutes post dose of each treatment period</time_frame>
        <population>All Subjects Population. Only those participants with data available at the indicated time points were analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Eligible participants received Placebo matching GSK2190915 oral solution which was administered with 100 mL of water on Day 1 of each treatment period.</description>
          </group>
          <group group_id="O2">
            <title>GSK2190915 10 mg</title>
            <description>Eligible participants received single dose 10 mg GSK2190915 oral solution which was administered with 100 mL of water on Day 1 of each treatment period.</description>
          </group>
          <group group_id="O3">
            <title>GSK2190915 50 mg</title>
            <description>Eligible participants received single dose 50 mg GSK2190915 oral solution which was administered with 100 mL of water on Day 1 of each treatment period.</description>
          </group>
          <group group_id="O4">
            <title>GSK2190915 100 mg</title>
            <description>Eligible participants received single dose 100 mg GSK2190915 oral solution which was administered with 100 mL of water on Day 1 of each treatment period.</description>
          </group>
          <group group_id="O5">
            <title>GSK2190915 200 mg</title>
            <description>Eligible participants received single dose 200 mg GSK2190915 oral solution which was administered with 100 mL of water on Day 1 of each treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Hematology Parameters: Mean Corpuscle Hemoglobin (MCH)</title>
          <description>Blood samples were collected for the assessment of hematology parameter for MCH at pre dose and 25 hours and 30 minutes post dose. Participants had to fast for at least 8 hours prior to visit. During treatment periods, fasting continued until a light meal was allowed 1 hour post dose.</description>
          <population>All Subjects Population. Only those participants with data available at the indicated time points were analyzed</population>
          <units>Picograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="47"/>
                <count group_id="O4" value="45"/>
                <count group_id="O5" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="44"/>
                    <count group_id="O2" value="44"/>
                    <count group_id="O3" value="47"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.27" spread="2.078"/>
                    <measurement group_id="O2" value="30.14" spread="2.122"/>
                    <measurement group_id="O3" value="30.30" spread="2.032"/>
                    <measurement group_id="O4" value="30.25" spread="2.024"/>
                    <measurement group_id="O5" value="30.14" spread="2.008"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>25 Hours 30 Minutes</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="45"/>
                    <count group_id="O3" value="46"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.19" spread="2.157"/>
                    <measurement group_id="O2" value="30.20" spread="2.050"/>
                    <measurement group_id="O3" value="30.27" spread="2.076"/>
                    <measurement group_id="O4" value="30.18" spread="2.050"/>
                    <measurement group_id="O5" value="30.32" spread="2.102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assessment of Hematology Parameters: Mean Corpuscle Volume (MCV)</title>
        <description>Blood samples were collected for the assessment of hematology parameter for MCV at pre dose and 25 hours and 30 minutes post dose. Participants had to fast for at least 8 hours prior to visit. During treatment periods, fasting continued until a light meal was allowed 1 hour post dose.</description>
        <time_frame>Pre dose and 25 hours and 30 minutes post dose of each treatment period</time_frame>
        <population>All Subjects Population. Only those participants with data available at the indicated time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Eligible participants received Placebo matching GSK2190915 oral solution which was administered with 100 mL of water on Day 1 of each treatment period.</description>
          </group>
          <group group_id="O2">
            <title>GSK2190915 10 mg</title>
            <description>Eligible participants received single dose 10 mg GSK2190915 oral solution which was administered with 100 mL of water on Day 1 of each treatment period.</description>
          </group>
          <group group_id="O3">
            <title>GSK2190915 50 mg</title>
            <description>Eligible participants received single dose 50 mg GSK2190915 oral solution which was administered with 100 mL of water on Day 1 of each treatment period.</description>
          </group>
          <group group_id="O4">
            <title>GSK2190915 100 mg</title>
            <description>Eligible participants received single dose 100 mg GSK2190915 oral solution which was administered with 100 mL of water on Day 1 of each treatment period.</description>
          </group>
          <group group_id="O5">
            <title>GSK2190915 200 mg</title>
            <description>Eligible participants received single dose 200 mg GSK2190915 oral solution which was administered with 100 mL of water on Day 1 of each treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Hematology Parameters: Mean Corpuscle Volume (MCV)</title>
          <description>Blood samples were collected for the assessment of hematology parameter for MCV at pre dose and 25 hours and 30 minutes post dose. Participants had to fast for at least 8 hours prior to visit. During treatment periods, fasting continued until a light meal was allowed 1 hour post dose.</description>
          <population>All Subjects Population. Only those participants with data available at the indicated time points were analyzed.</population>
          <units>Femtoliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="47"/>
                <count group_id="O4" value="45"/>
                <count group_id="O5" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="44"/>
                    <count group_id="O2" value="44"/>
                    <count group_id="O3" value="47"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.85" spread="5.589"/>
                    <measurement group_id="O2" value="88.75" spread="5.500"/>
                    <measurement group_id="O3" value="88.80" spread="5.464"/>
                    <measurement group_id="O4" value="88.96" spread="5.673"/>
                    <measurement group_id="O5" value="89.06" spread="5.703"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>25 Hours 30 Minutes</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="45"/>
                    <count group_id="O3" value="46"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.74" spread="6.116"/>
                    <measurement group_id="O2" value="88.57" spread="5.612"/>
                    <measurement group_id="O3" value="88.89" spread="5.696"/>
                    <measurement group_id="O4" value="88.69" spread="5.625"/>
                    <measurement group_id="O5" value="89.23" spread="5.730"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assessment of Hematology Parameters: Red Blood Cell Count (RBC)</title>
        <description>Blood samples were collected for the assessment of hematology parameter for RBC at pre dose and 25 hours and 30 minutes post dose. Participants had to fast for at least 8 hours prior to visit. During treatment periods, fasting continued until a light meal was allowed 1 hour post dose.</description>
        <time_frame>Pre dose and 25 hours and 30 minutes post dose of each treatment period</time_frame>
        <population>All Subjects Population. Only those participants with data available at the indicated time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Eligible participants received Placebo matching GSK2190915 oral solution which was administered with 100 mL of water on Day 1 of each treatment period.</description>
          </group>
          <group group_id="O2">
            <title>GSK2190915 10 mg</title>
            <description>Eligible participants received single dose 10 mg GSK2190915 oral solution which was administered with 100 mL of water on Day 1 of each treatment period.</description>
          </group>
          <group group_id="O3">
            <title>GSK2190915 50 mg</title>
            <description>Eligible participants received single dose 50 mg GSK2190915 oral solution which was administered with 100 mL of water on Day 1 of each treatment period.</description>
          </group>
          <group group_id="O4">
            <title>GSK2190915 100 mg</title>
            <description>Eligible participants received single dose 100 mg GSK2190915 oral solution which was administered with 100 mL of water on Day 1 of each treatment period.</description>
          </group>
          <group group_id="O5">
            <title>GSK2190915 200 mg</title>
            <description>Eligible participants received single dose 200 mg GSK2190915 oral solution which was administered with 100 mL of water on Day 1 of each treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Hematology Parameters: Red Blood Cell Count (RBC)</title>
          <description>Blood samples were collected for the assessment of hematology parameter for RBC at pre dose and 25 hours and 30 minutes post dose. Participants had to fast for at least 8 hours prior to visit. During treatment periods, fasting continued until a light meal was allowed 1 hour post dose.</description>
          <population>All Subjects Population. Only those participants with data available at the indicated time points were analyzed.</population>
          <units>Cells x 10^12 per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="47"/>
                <count group_id="O4" value="45"/>
                <count group_id="O5" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="44"/>
                    <count group_id="O2" value="44"/>
                    <count group_id="O3" value="47"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.038" spread="0.4699"/>
                    <measurement group_id="O2" value="5.086" spread="0.4255"/>
                    <measurement group_id="O3" value="5.005" spread="0.4853"/>
                    <measurement group_id="O4" value="5.050" spread="0.4044"/>
                    <measurement group_id="O5" value="5.030" spread="0.4756"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>25 Hours 30 Minutes</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="45"/>
                    <count group_id="O3" value="46"/>
                    <count group_id="O4" value="45"/>
                    <count group_id="O5" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.018" spread="0.3819"/>
                    <measurement group_id="O2" value="5.039" spread="0.4533"/>
                    <measurement group_id="O3" value="5.023" spread="0.4253"/>
                    <measurement group_id="O4" value="5.025" spread="0.4112"/>
                    <measurement group_id="O5" value="4.998" spread="0.4557"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)</title>
        <description>An AE is any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect and medically significant.</description>
        <time_frame>Up to follow up (7 to 21 days) following last dose</time_frame>
        <population>All Subjects Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Eligible participants received Placebo matching GSK2190915 oral solution which was administered with 100 mL of water on Day 1 of each treatment period.</description>
          </group>
          <group group_id="O2">
            <title>GSK2190915 10 mg</title>
            <description>Eligible participants received single dose 10 mg GSK2190915 oral solution which was administered with 100 mL of water on Day 1 of each treatment period.</description>
          </group>
          <group group_id="O3">
            <title>GSK2190915 50 mg</title>
            <description>Eligible participants received single dose 50 mg GSK2190915 oral solution which was administered with 100 mL of water on Day 1 of each treatment period.</description>
          </group>
          <group group_id="O4">
            <title>GSK2190915 100 mg</title>
            <description>Eligible participants received single dose 100 mg GSK2190915 oral solution which was administered with 100 mL of water on Day 1 of each treatment period.</description>
          </group>
          <group group_id="O5">
            <title>GSK2190915 200 mg</title>
            <description>Eligible participants received single dose 200 mg GSK2190915 oral solution which was administered with 100 mL of water on Day 1 of each treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)</title>
          <description>An AE is any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect and medically significant.</description>
          <population>All Subjects Population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="47"/>
                <count group_id="O4" value="45"/>
                <count group_id="O5" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change From Baseline in Blood Leukotriene B4 (LTB4)</title>
        <description>Analysis LTB4 levels in the blood samples indicated the extent of LTB4 inhibition following administration of GSK2190915 compared to Baseline. Baseline was the pre dose value. Change from Baseline was calculated by subtracting the Baseline values from the individual post-randomization values.</description>
        <time_frame>Baseline (pre dose) up to 24 Hours post dose of each treatment period</time_frame>
        <population>Pharmacodynamics (PD) Population was defined as participants in the All Subjects Population for whom a PD sample (blood or urine) was obtained and analyzed. Only those participants available at the indicated time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Eligible participants received Placebo matching GSK2190915 oral solution which was administered with 100 mL of water on Day 1 of each treatment period.</description>
          </group>
          <group group_id="O2">
            <title>GSK2190915 10 mg</title>
            <description>Eligible participants received single dose 10 mg GSK2190915 oral solution which was administered with 100 mL of water on Day 1 of each treatment period.</description>
          </group>
          <group group_id="O3">
            <title>GSK2190915 50 mg</title>
            <description>Eligible participants received single dose 50 mg GSK2190915 oral solution which was administered with 100 mL of water on Day 1 of each treatment period.</description>
          </group>
          <group group_id="O4">
            <title>GSK2190915 100 mg</title>
            <description>Eligible participants received single dose 100 mg GSK2190915 oral solution which was administered with 100 mL of water on Day 1 of each treatment period.</description>
          </group>
          <group group_id="O5">
            <title>GSK2190915 200 mg</title>
            <description>Eligible participants received single dose 200 mg GSK2190915 oral solution which was administered with 100 mL of water on Day 1 of each treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change From Baseline in Blood Leukotriene B4 (LTB4)</title>
          <description>Analysis LTB4 levels in the blood samples indicated the extent of LTB4 inhibition following administration of GSK2190915 compared to Baseline. Baseline was the pre dose value. Change from Baseline was calculated by subtracting the Baseline values from the individual post-randomization values.</description>
          <population>Pharmacodynamics (PD) Population was defined as participants in the All Subjects Population for whom a PD sample (blood or urine) was obtained and analyzed. Only those participants available at the indicated time points were analyzed.</population>
          <units>Percent change</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>2 Hours, Pre exercise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-37.32" lower_limit="-57.8" upper_limit="241.4"/>
                    <measurement group_id="O2" value="-29.32" lower_limit="-78.4" upper_limit="125.3"/>
                    <measurement group_id="O3" value="-87.65" lower_limit="-99.6" upper_limit="78.9"/>
                    <measurement group_id="O4" value="-97.98" lower_limit="-99.7" upper_limit="25.9"/>
                    <measurement group_id="O5" value="-98.43" lower_limit="-100.0" upper_limit="-55.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9.5 Hours, Pre exercise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.82" lower_limit="-74.6" upper_limit="239.4"/>
                    <measurement group_id="O2" value="-23.43" lower_limit="-93.4" upper_limit="31.1"/>
                    <measurement group_id="O3" value="-87.74" lower_limit="-98.4" upper_limit="-23.0"/>
                    <measurement group_id="O4" value="-96.53" lower_limit="-99.4" upper_limit="-45.2"/>
                    <measurement group_id="O5" value="-99.78" lower_limit="-100.0" upper_limit="-95.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 Hours, Pre exercise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.59" lower_limit="-57.2" upper_limit="235.1"/>
                    <measurement group_id="O2" value="-9.56" lower_limit="-83.3" upper_limit="167.9"/>
                    <measurement group_id="O3" value="-84.49" lower_limit="-96.7" upper_limit="-36.3"/>
                    <measurement group_id="O4" value="-70.00" lower_limit="-97.8" upper_limit="209.4"/>
                    <measurement group_id="O5" value="-98.75" lower_limit="-99.8" upper_limit="-64.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change From Baseline in Urine Leukotriene E4 (LTE4)</title>
        <description>Analysis of LTE4 levels in the urine samples indicated the extent of LTE4 inhibition following administration of GSK2190915 compared to Baseline. Baseline was the pre dose value. Change from Baseline was calculated by subtracting the Baseline values from the individual post-randomization values.</description>
        <time_frame>Baseline (pre dose) up to 24 Hours post dose of each treatment period</time_frame>
        <population>PD Population. Only those participants available at the indicated time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Eligible participants received Placebo matching GSK2190915 oral solution which was administered with 100 mL of water on Day 1 of each treatment period.</description>
          </group>
          <group group_id="O2">
            <title>GSK2190915 10 mg</title>
            <description>Eligible participants received single dose 10 mg GSK2190915 oral solution which was administered with 100 mL of water on Day 1 of each treatment period.</description>
          </group>
          <group group_id="O3">
            <title>GSK2190915 50 mg</title>
            <description>Eligible participants received single dose 50 mg GSK2190915 oral solution which was administered with 100 mL of water on Day 1 of each treatment period.</description>
          </group>
          <group group_id="O4">
            <title>GSK2190915 100 mg</title>
            <description>Eligible participants received single dose 100 mg GSK2190915 oral solution which was administered with 100 mL of water on Day 1 of each treatment period.</description>
          </group>
          <group group_id="O5">
            <title>GSK2190915 200 mg</title>
            <description>Eligible participants received single dose 200 mg GSK2190915 oral solution which was administered with 100 mL of water on Day 1 of each treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change From Baseline in Urine Leukotriene E4 (LTE4)</title>
          <description>Analysis of LTE4 levels in the urine samples indicated the extent of LTE4 inhibition following administration of GSK2190915 compared to Baseline. Baseline was the pre dose value. Change from Baseline was calculated by subtracting the Baseline values from the individual post-randomization values.</description>
          <population>PD Population. Only those participants available at the indicated time points were analyzed.</population>
          <units>Percent change</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>2 Hours, Pre exercise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.30" lower_limit="-13.3" upper_limit="89.6"/>
                    <measurement group_id="O2" value="-19.68" lower_limit="-58.1" upper_limit="5.4"/>
                    <measurement group_id="O3" value="-12.58" lower_limit="-76.8" upper_limit="971.1"/>
                    <measurement group_id="O4" value="-9.71" lower_limit="-53.8" upper_limit="24.4"/>
                    <measurement group_id="O5" value="-12.29" lower_limit="-65.3" upper_limit="55.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 Hours, 1 Hour 30 Minutes post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.61" lower_limit="-49.0" upper_limit="83.6"/>
                    <measurement group_id="O2" value="-28.97" lower_limit="-84.4" upper_limit="1.4"/>
                    <measurement group_id="O3" value="-39.12" lower_limit="-81.9" upper_limit="920.7"/>
                    <measurement group_id="O4" value="-28.67" lower_limit="-71.0" upper_limit="18.3"/>
                    <measurement group_id="O5" value="-30.02" lower_limit="-85.6" upper_limit="53.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9.5 Hours, Pre exercise post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.82" lower_limit="-42.4" upper_limit="37.9"/>
                    <measurement group_id="O2" value="-52.76" lower_limit="-86.0" upper_limit="0.3"/>
                    <measurement group_id="O3" value="-66.74" lower_limit="-86.4" upper_limit="629.8"/>
                    <measurement group_id="O4" value="-59.85" lower_limit="-98.2" upper_limit="-23.1"/>
                    <measurement group_id="O5" value="-70.43" lower_limit="-87.7" upper_limit="-27.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9.5 Hours, 1 Hour 30 Minutes post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.96" lower_limit="-49.0" upper_limit="88.5"/>
                    <measurement group_id="O2" value="-45.05" lower_limit="-89.3" upper_limit="-15.9"/>
                    <measurement group_id="O3" value="-61.86" lower_limit="-86.6" upper_limit="-0.3"/>
                    <measurement group_id="O4" value="-63.67" lower_limit="-83.5" upper_limit="-42.1"/>
                    <measurement group_id="O5" value="-81.03" lower_limit="-94.4" upper_limit="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 Hours, Pre exercise post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.04" lower_limit="-50.3" upper_limit="24.1"/>
                    <measurement group_id="O2" value="-29.26" lower_limit="-82.6" upper_limit="21.3"/>
                    <measurement group_id="O3" value="-70.37" lower_limit="-88.7" upper_limit="24.9"/>
                    <measurement group_id="O4" value="-72.55" lower_limit="-99.5" upper_limit="-5.7"/>
                    <measurement group_id="O5" value="-77.07" lower_limit="-99.1" upper_limit="-34.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Derived Pharmacokinetic (PK) Parameters for GSK2190915</title>
        <description>PK samples were supposed to be collected at 10 minutes prior to the exercise challenge at 2 hours, 9.5 hours and 24 hours.</description>
        <time_frame>Pre dose, 2 hours, 3.5 hours, 9.5 hours, 11 hours and 24 hours following exercise challenge of each treatment period</time_frame>
        <population>PK Population was defined as participants in the All Subjects Population for whom a PK sample was obtained and analyzed. Data was not collected for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2190915 10 mg</title>
            <description>Eligible participants received single dose 10 mg GSK2190915 oral solution which was administered with 100 mL of water on Day 1 of each treatment period.</description>
          </group>
          <group group_id="O2">
            <title>GSK2190915 50 mg</title>
            <description>Eligible participants received single dose 50 mg GSK2190915 oral solution which was administered with 100 mL of water on Day 1 of each treatment period.</description>
          </group>
          <group group_id="O3">
            <title>GSK2190915 100 mg</title>
            <description>Eligible participants received single dose 100 mg GSK2190915 oral solution which was administered with 100 mL of water on Day 1 of each treatment period.</description>
          </group>
          <group group_id="O4">
            <title>GSK2190915 200 mg</title>
            <description>Eligible participants received single dose 200 mg GSK2190915 oral solution which was administered with 100 mL of water on Day 1 of each treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Derived Pharmacokinetic (PK) Parameters for GSK2190915</title>
          <description>PK samples were supposed to be collected at 10 minutes prior to the exercise challenge at 2 hours, 9.5 hours and 24 hours.</description>
          <population>PK Population was defined as participants in the All Subjects Population for whom a PK sample was obtained and analyzed. Data was not collected for this outcome measure.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>AEs were collected up to follow up (up to 7 to 21 days following last dose).</time_frame>
      <desc>All Subjects Population was used.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Eligible participants received Placebo matching GSK2190915 oral solution which was administered with 100 mL of water on Day 1 of the treatment period.</description>
        </group>
        <group group_id="E2">
          <title>GSK2190915 10 mg</title>
          <description>Eligible participants received single dose 10 mg GSK2190915 oral solution which was administered with 100 mL of water on Day 1 of the treatment period.</description>
        </group>
        <group group_id="E3">
          <title>GSK2190915 50 mg</title>
          <description>Eligible participants received single dose 50 mg GSK2190915 oral solution which was administered with 100 mL of water on Day 1 of the treatment period.</description>
        </group>
        <group group_id="E4">
          <title>GSK2190915 100 mg</title>
          <description>Eligible participants received single dose 100 mg GSK2190915 oral solution which was administered with 100 mL of water on Day 1 of the treatment period.</description>
        </group>
        <group group_id="E5">
          <title>GSK2190915 200 mg</title>
          <description>Eligible participants received single dose 200 mg GSK2190915 oral solution which was administered with 100 mL of water on Day 1 of the treatment period.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 12.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Tension headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

